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“Before I came here I was confused about this subject. After listening 
to your lecture, I am still confused but at a higher level.”  
–Enrico Fermi 
 
4 
ABSTRACT 
Dominant mutations in mitochondrial replicative helicase TWINKLE are a 
common cause of autosomal dominant progressive external ophthalmoplegia 
(AdPEO), a mitochondrial myopathy characterized by accumulation of 
multiple mtDNA deletions and respiratory chain deficiency in muscle, heart 
and central nervous system. Our research group has previously generated a 
transgenic mouse, Deletor, that replicates the main pathological 
characteristics of the AdPEO-disease. Studies on the Deletor have revealed 
induction of local stress response in the muscle that involved expression and 
secretion of a metabolic hormone, Fibroblast growth factor 21 (FGF21). In 
physiological nutritional challenges, FGF21 is known to be secreted by the liver 
to enhance energy-metabolism. Therefore, high levels of circulating FGF21 in 
mitochondrial disease expose the whole body to non-homeostatic, chronically 
altered metabolic state.  
The overall aim of this thesis was to characterize the stress responses and 
metabolic rearrangements upon mitochondrial myopathy with special 
emphasis on the actions of FGF21. We utilized valuable biopsy and serum 
samples of patients in parallel analyses with the Deletor and other established 
mouse models, and generated a new Deletor-FGF21 knockout model. 
First, to characterize the metabolic status of the affected muscle tissue, we 
utilized mass-spectrometric metabolomics and transcriptional analyses. 
Overall, the metabolic signature of the muscle was conserved in AdPEO 
patients and Deletor including rearrangement of one-carbon, folate and 
nucleotide metabolism. Moreover, the muscle and heart of the Deletor 
presented with robust induction of glucose-driven serine synthesis and 
glutathione production, demonstrated with in vivo radiotracer and flux-omics 
assays. Together, these novel metabolic rearrangements and the previously 
characterized transcriptional stress response are hereafter collectively called 
the mammalian mitochondrial integrated stress response, or ISRmt.  
Next, we studied the dynamics of the pathological events in the muscle by 
analyzing ISRmt markers at different stages of manifestation in the Deletor. At 
the time when the first histological signs of mitochondrial dysfunction are 
detected (<12 months of age) the mitochondrial folate cycle and endocrine 
hormones FGF21 and GDF15 were induced. Several months later, when some 
of the affected muscle fibers already manifest with pathological mitochondrial 
proliferation, we detected induction of serine de novo synthesis enzymes, 
marking initiation for the glucose driven metabolic rearrangements. 
Importantly, characterization of muscle pathology of the Deletor-FGF21KO 
model revealed that FGF21 drives the progression of ISRmt to the advanced 
metabolic stage, whereas the molecular and histological disease hallmarks, or 
expression of the first-stage ISRmt markers, were not affected by presence or 
absence of FGF21.  
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Systematic phenotypic characterization of the Deletor-FGF21KO showed 
that FGF21 expectedly advanced white adipose tissue browning and loss of 
systemic adiposity in the Deletor. Moreover, we demonstrated that tissue-level 
glucose preferences were altered in the whole brain and peripheral organs of 
Deletor by FGF21. Additionally, we described a completely new central 
nervous system pathology in the Deletor. Importantly, we showed that, 
although the mtDNA deletion formation is uniform in the brain of Deletor, 
only a specific CA2-region of hippocampus manifests with mitochondrial 
respiratory chain pathology combined with intensive glucose uptake.  
The second part of this thesis involved clinical characterization of the 
circulating biomarkers of mitochondrial diseases, FGF21 and GDF15. In our 
combined meta-analysis and retrospective measurements, we confirmed that 
both FGF21 and GDF15 outperform the traditional metabolite markers of 
mitochondrial disease. Interestingly, however, among the mitochondrial 
myopathy patients and representative mouse models, we found that high 
levels of serum FGF21 and GDF15 were characteristic for mitochondrial 
myopathies caused by primary or secondary mitochondrial translation defects, 
whereas primary OXPHOS mutations did not induce the same response, 
important to acknowledge in diagnostics and mechanistic studies in the future.  
In summary, studies of this thesis present for the first time the conserved 
whole-cellular metabolic rearrangements of the muscle upon mtDNA 
maintenance defects. We also present indispensable roles for FGF21 in 
regulation of local and systemic disease progression in a physiological model 
of mitochondrial myopathy. Together, our pre-clinical and clinical analyses on 
the stress responses upon different mitochondrial insults have unlocked novel 
research directions and serve the mitochondrial disease diagnostics, follow-up 
and evaluation of treatment trials in the future. 
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1 INTRODUCTION 
Evolution of the eukaryotic cells is marked by compartmentalization of 
metabolism (Bolte, 2015). For example, synthesis and breakdown of fatty acids 
is separated between cytoplasm, mitochondria and peroxisomes, and 
regulated by shuttling of precursors and intermediates between the 
compartments. Some metabolic pathways are partitioned between cytoplasm 
and mitochondria to form complete functional metabolic cycles, e.g. the folate 
cycle. Perhaps the most famous function of mitochondria is to perform final 
oxidation of carbohydrates and fatty acids, followed by oxidative 
phosphorylation. Oxidative phosphorylation, or OXPHOS, is the most efficient 
way to produce the conserved energy currency of the cell, ATP, and 
simultaneously maintain redox-status of the cell.  
Properly functioning OXPHOS of the eukaryotic cell needs coordinated 
expression of nuclear factors and the organellar genome of mitochondria, 
mtDNA. MtDNA is a circular genome that only encodes a handful of OXPHOS 
enzyme subunits and all RNA-molecules needed for in-organelle translation 
of mtDNA transcripts. Mutations in the mtDNA and its nuclear-encoded 
maintenance factors are the most frequent causes of mitochondrial diseases.  
Mitochondrial diseases are a spectrum of disorders fundamentally 
characterized by impaired respiratory chain and OXPHOS, failures in which 
compromise energy metabolism and maintenance of the balanced oxidative 
environment for various enzymatic reactions. Symptoms and tissue-specific 
manifestations vary tremendously from one disorder to another – spanning 
from infertility and adult-onset myopathy to fatal seizures and metabolic crisis 
of an infant (Ylikallio, 2012). Mitochondrial diseases are known to be sensitive 
to environmental input, nutritional status and developmental state of an 
individual, and altered hormonal signaling could have a critical effect in the 
pathophysiology of a disease. Therefore, mitochondrial diseases are difficult 
to diagnose and after decades of research have still remained incurable. 
Characterization of local and systemic metabolic rearrangements, and factors 
that regulate those events, are key for understanding the mechanisms that 
allow better diagnostics, enable identification of new therapy targets and serve 
in evaluation of treatment trials in the future (Suomalainen, 2018). 
In this thesis, we have investigated the stress responses in mitochondrial 
diseases in vivo.  
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2 REVIEW OF THE LITERATURE 
2.1 FUNDAMENTALS OF ENERGETICS IN 
MITOCHONDRIA 
2.1.1 STRUCTURE, DYNAMICS AND DYNAMIC STRUCTURE 
Mitochondria are intracellular organelles with several specific characteristics: 
in the animal kingdom, they are the only organelles with their own DNA (Nass, 
1965), protein synthesis apparatus (McLean JR, Cohn GL, Brandt IK, 1958; 
Wintersberger, 1964), and they are electrochemically charged (Mitchell, 1961). 
The main tasks of mitochondria involve a variety of biosynthetic functions 
from ATP synthesis and redox-regulation to synthesis of sulfur clusters and 
metal metabolism.  
The origin of mitochondria is approximated to have taken place 1.5 billion 
years ago in an event of endosymbiosis (Sagan (née Margulis), 1967). 
According to a widely-accepted theory an anaerobic eukaryote engulfed a 
prokaryotic endosymbiont. It has also been suggested that an archaeon 
engulfed aerobic proteobacteria, and that event sparked the separation of the 
eukaryotes from the lineage of archaea (discussed in Lane 2017). Although 
speculations on the exact primitive benefit for the host from having an 
endosymbiont have not reached conclusion, the eukaryotic cells with 
mitochondria are the only ones that compose complex multicellular life-forms. 
According to bioenergetic calculations, the membrane surface area devoted for 
energy production in mitochondria enabled formation, maintenance and 
abundant expression of enormous nuclear genomes, and therefore led to 
emergence of the multigenic eukaryote-specific traits, e.g. cell cycle, sexual 
dimorphism, endomembrane trafficking and the nucleus (discussed in Lane 
and Martin 2010).  
Structure and functions of the eukaryotic mitochondria still resemble 
closely the prokaryotic systems, reflecting their evolutionary ancestry. 
Mitochondria have two lipid bilayers, the outer and inner membranes which 
enclose two chemically distinct compartments, intermembrane space and 
mitochondrial matrix. The physical barriers formed by the two membranes 
maintain mitochondrial membrane potential, an electrochemical proton 
gradient across the inner membrane (Figure 2). Essentially, failure to 
maintain the mitochondrial membrane potential is penalized by collapsed 
energy production, transmembrane transport and cell death (Zorova, 2018). 
Structurally, the inner mitochondrial membrane is intensively folded to form 
cristae structures that protrude to the matrix. The cristae are extremely 
protein rich, occupied e.g. by OXPHOS complexes. The mitochondrial matrix 
is an active center of metabolism, occupied by essential enzymes of 
carbohydrate and fatty acid oxidation as well as tens of biosynthetic pathways.  
Review of the literature 
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The great majority of the approximately 1200 mitochondrially targeted 
proteins (Calvo, 2016) are nuclear encoded and synthesized in the cytoplasm. 
Those proteins, as well as most metabolism intermediates, need regulated 
transport through the outer and inner membranes, while some small 
molecules can freely diffuse in and out of mitochondria (Fox, 2012; Palmieri, 
2014). 
Mitochondria of one cell form extremely complex and dynamic networks 
dependent on cell type and metabolic status. Mitochondria undergo constant 
fission and fusion events that are carried out by distinct machineries in close 
contact with cytoskeleton and endoplasmic reticulum (Kuznetsov, 2013; 
Lewis, 2016; Pernas, 2016; Rieusset, 2018). Impairment of fission or fusion 
machineries cause optic atrophy and neuromuscular diseases (Delettre, 2002; 
Züchner, 2004). The dynamic movement and transportation of mitochondria 
is powered by kinesin and dynamin motor proteins along microtubule tracks, 
or along actin filaments by myosin motors (Hollenbeck, 2005). Proper 
transportation of mitochondria along polarized structures, such as axons of 
neurons, is important for cellular fitness (Ferreirinha, 2004), and has reported 
implications even in common neurodegenerative disorders, such as 
Alzheimer’s and Parkinson’s diseases (Takihara, 2015; Zheng, 2019).  
2.1.2 THE POWERHOUSE 
Metabolism is the sum of chemical transformations in a cell or an organism. 
Metabolic pathways are divided into catabolic and anabolic processes that 
respectively break down or synthetize organic macromolecules. Catabolic 
reactions convert energy-rich macronutrients to smaller end-products. In the 
oxidative reactions, electrons are released and the energy is conserved in the 
form of ATP or reduced electron carriers and cofactors. These high-energy 
products of oxidative catabolism are correspondingly consumed by anabolic 
biosynthesis.  
Mitochondrial OXPHOS is the most productive and efficient machinery for 
ATP production in mammalian cells. Therefore, mitochondria have been 
called the powerhouse of the cell. However, maintenance of the correct ratios 
between the reduced and oxidized electron carriers is as important as 
maintaining levels of ATP, since numerous enzymatic reactions are regulated 
by the reductive state of the cell. (Nelson and Cox, 2008, part II, chapters 13-
23). 
The mitochondrial matrix hosts enzymatic machineries for final catabolism 
of carbohydrates and fatty acids, tricarboxylic acid cycle (TCA, also called citric 
acid or Krebs cycle) and beta oxidation, respectively. The main end-products 
of TCA cycle and beta oxidation are the reduced cofactors, nicotinamide 
adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH2), that 
are utilized by mitochondrial OXPHOS to 1) produce ATP and 2) retain the 
levels of oxidized cofactors NAD+ and FAD+ (Figure 1) (Nelson and Cox, 2008, 
chapter 13-14; Martínez-Reyes, 2016). 
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Figure 1' Oxidative energy metabolism in mitochondria. Fatty acid beta oxidation and TCA 
cycle conserve energy from dietary fats and carbohydrates in form of reduced 
electron carriers, NADH and FADH2. Electron transport chain and OXPHOS 
generate ATP, and regenerate the oxidized cofactors NAD+ and FAD+ (see also 
Figure 2). Abbreviations: CPTI(II)= carnitine acyltransferase I(II). 
!"#"!"#$ %&'$()(*+$,-$(+./01*$,.$23,41/,5+$(1/162*,-7$28$(10629)401/+-$
1.4$81//)$1(,4-$$
 
The TCA cycle oxidizes metabolic intermediates in cyclic reactions that release 
CO2. The oxidative reactions generate electrons that are conserved in NADH 
and FADH2. In addition, one molecule of ATP or GTP is produced per cycle. In 
oxidative nutrient rich conditions, acetyl coenzyme A (acetyl-CoA), is accepted 
as the primary substrate for the TCA cycle. The main producers of acetyl-CoA 
are fatty acid oxidation and glycolysis (Shi, 2015). Conversely, upon scarce 
nutrition or specific biosynthetic need, the TCA cycle can be utilized by the cell 
in intermediary metabolic reactions, allowing alternative entry and 
interconversion of TCA cycle metabolites, amino acids and nucleic acids 
(Boroughs, 2015) (Figure 1).  
Glucose provides easily accessible energy for the cell. In nutrient rich 
conditions catabolism of dietary and storage carbohydrates dominate energy 
metabolism. Cytoplasmic glycolysis consists of preparatory and energy 
conserving phases. The preparatory phase consumes ATP and produces three-
carbon intermediates for further catalysis or biosynthetic reactions. For 
example, glycolysis intermediates glyceraldehyde-3-phosphate (G3P) and 3-
phosphoglycerate (3-PG) serve as precursors for membrane lipids and de novo 
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synthesis of non-essential amino acids, respectively (Vander Heiden, 2009). 
The energy conserving pay-off phase produces three-carbon metabolite 
pyruvate, and generates ATP and NADH. Pyruvate is transported to 
mitochondria and further oxidized into a two-carbon acetyl-CoA molecule for 
oxidation in the TCA cycle. (Nelson and Cox, 2008, chapter 14). 
Fatty acids are breakdown products of dietary fats. Fatty acids are 
structurally variable with regard to the length of the carbon chain and presence 
and abundance of double bonds in the backbone (saturated vs. unsaturated 
fatty acids). For metabolic utilization (catabolic or anabolic), the free fatty 
acids are activated by addition of coenzyme A, yielding fatty acyl-CoA in 
reactions where ATP is consumed. The mitochondrial outer membrane is 
occupied by general acyl-CoA synthetases that have specificity for different 
lengths of fatty acids. To be catabolized in the mitochondrial beta oxidation, 
long chain fatty acids (14 or more carbons) require a specific shuttle for import 
into the matrix. In the import machinery the fatty acid moiety of a fatty acyl-
CoA is transiently bound to carnitine by carnitine acyltransferase I (CPTI) 
enzyme on the outer mitochondrial membrane. The conversion of fatty acids 
into carnitine esters commits the molecules for oxidative breakdown in 
mitochondria. Fatty acyl-carnitines enter the mitochondrial matrix by 
facilitated diffusion by acyl-carnitine/carnitine transporter of the inner 
mitochondrial membrane. On the inner mitochondrial membrane, the fatty 
acyl-carnitines are converted to intramitochondrial fatty acyl-CoA by CPTII. 
Depending on length of the acyl-chain, beta oxidation of the fatty acyl-CoAs 
yield a varying amount of two carbon acetyl-CoA units for TCA cycle and 
NADH and FADH2 species for OXPHOS. (Kerner, 2000; Nelson and Cox, 
2008, chapter 17). 
2.1.2.2 Oxidative phosphorylation 
To synthetize ATP, the mitochondrial respiratory chain has to prime the 
reaction by generating a driving force, an electrochemical gradient across the 
mitochondrial inner membrane, the mitochondrial membrane potential 
(Mitchell, 1961). The membrane potential is mainly the net difference between 
concentration of protons (=hydrogen ions, H+) in the matrix (=low) and 
intermembrane space (=high). Protons are actively pumped in the 
intermembrane space by the respiratory chain enzyme complexes. The 
pumping is energized by transfer of electrons (e-) derived from the reduced 
cofactors NADH and FADH2. The electrons are shuttled throughout the 
respiratory chain, or sometimes called the electron transfer chain, to the final 
acceptor, molecular oxygen (=respiration). ATP synthase enzyme links the 
movement of protons down their electrochemical gradient (=protonmotive 
force) to covalent attachment of an inorganic phosphate to a molecule of ADP, 
generating ATP (Figure 2). (Saraste, 1999; Nelson and Cox, 2008, chapter 19). 
The respiratory chain consists of multiprotein complexes (I-IV) and soluble 
electron carriers of inner membrane. Together, the respiratory chain 
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complexes and ATP synthase (Complex V) form the complete oxidative ATP 
production unit, OXPHOS.  
Complex I and Complex II of the respiratory chain accept the electrons 
released from the breakdown of macronutrients and metabolites. Complex I, 
or NADH dehydrogenase, accepts electrons by oxidizing NADH and 
regenerating NAD+. Along the transmembrane part of the enzyme, electrons 
are transported through iron-sulfur clusters to the lipid-soluble electron 
carrier ubiquinone, or coenzyme Q10. In the process, four protons are pumped 
into the intermembrane space. Complex II, or succinate dehydrogenase, 
transfers electrons from FADH2 to reduce ubiquinone, similarly as Complex I. 
Unlike other respiratory chain complexes, Complex II does not pump protons 
across the membrane and it also catalyzes oxidation of succinate to fumarate 
as part of the TCA cycle.  
Complex III, or coenzyme Q : cytochrome c oxidoreductase, acts between 
two solute electron carriers of the respiratory chain trafficking in the inner 
mitochondrial membrane. Complex III accepts electrons from ubiquinol 
(CoQ), the reduced form of ubiquinone, and passes them on to cytochrome c 
(CytC). Complex IV, or cytochrome c oxidase, transfers electrons from 
cytochrome c to molecular oxygen. In the process, protons are pumped into 
the intermembrane space by both Complexes III and IV.  
Complex V, or ATP synthase, catalyzes the enzymatic conversion of ADP to 
ATP. Complex V passes hydrogen ions through its transmembrane channel 
subunit. This movement of protons energizes conformational rotation in the 
catalytic unit. The alternating states of the catalytic unit either bind substrates 
ADP and inorganic phosphate (Pi) or release a newly synthetized ATP 
molecule. To power the thermodynamically unfavorable enzymatic reactions 
of the cytoplasm, ATP needs to be transported across mitochondrial 
membranes by active antiporter function of ADP/ATP translocase.  
(Saraste, 1999; Martínez-Reyes, 2016) 
 
Figure 2' Illustration of the mitochondrial OXPHOS complexes embedded in the inner 
mitochondrial membrane. Transfer of electrons (e-) from NADH and FADH2 to 
molecular oxygen is coupled to pumping of protons (H+) from matrix to 
intermembrane space by Complex I, III and IV. Controlled passing of protons from 
intermembrane space back to the matrix energizes phosphorylation of ADP to ATP 
by ATP synthase.  
Complex IVComplex III
NADH
FADH2
FAD+ O2
! H2O
ADP + Pi
ATP
Complex IIComplex I Complex V (ATPsynthase)
NAD+
H+
H+H+H+H+H+H+H+ H+H+ H+ H+H+H+
e-
e-
CoQ CytC
e-e-
e-
Mitochodnrial 
Matrix
Cytoplasm
Intermembrane 
space
Outer membrane
Inner membrane
H+
Review of the literature 
18 
Tight coupling of proton pumping by respiratory chain to ATP synthesis is 
not the only metabolic function of the proton gradient. Passing of protons 
through separate membrane channels of the inner membrane can uncouple 
the respiratory chain from Complex V. The rapid discharge of membrane 
potential generates heat. The dedicated uncoupling proteins of mammalian 
organisms (UCP1-3) have tissue-specific expression patterns and specialized 
functions in metabolic regulation, such as adaptive thermogenesis and ROS 
management (Hagen, 2002).   
2.1.2.3 Reactive oxygen species 
Electron transfer reactions and reduction of oxygen by the respiratory chain 
has potential to generate highly reactive oxygen radicals, so called reactive 
oxygen species (ROS). Reactions between Complex I and ubiquinone and 
ubiquinone and Complex III involve a radical intermediate that has potential 
to transfer an electron to oxygen, generating a superoxide radical (O2-) that 
can undergo further transformation to a hydroxyl free radical (•OH) (Zhao, 
2019). In healthy cells, ROS production is readily controlled by cellular 
superoxide dismutase enzymes and glutathione peroxidase, converting excess 
superoxides to hydrogen peroxide and water. Impaired electron transfer due 
to respiratory chain complex mutations can critically increase the amount of 
ROS, therefore contributing to generalized cellular pathogenesis through 
oxidation of lipids, enzymes and nucleic acids and through complex alterations 
in cellular signaling cascades (Schieber, 2014). Therefore, extensive ROS and 
cellular damage has been suggested as pathophysiological hallmarks of 
primary mitochondrial diseases (Lenaz, 1998) but pathological adverse effects 
have been described also in other neurodegenerative disorders (Coyle, 1993). 
The various roles and importance of ROS, however, are not completely 
understood. ROS has shown to play important roles in sensing and signaling 
of normal physiological conditions and challenges (Chandel, 2007; Ahlqvist, 
2015; Hämäläinen, 2015; Dogan, 2018), highlighting the necessity of a 
controlled ROS environment.  
2.2 MTDNA AND MITOCHONDRIAL GENETICS 
The Mitochondrial genome, mtDNA, is organized as a supercoiled double-
helical circular molecule. In humans and mice, mtDNA is approximately 
16,600 base pairs in length. The two strands of mtDNA are called the heavy 
and light strands. Heavy strand is particularly GC-rich and mainly consists of 
coding regions, whereas the light strand is relatively gene-poor. Broadly, the 
mtDNA is extremely compact: gene areas generally lack introns and regulatory 
sequences are concentrated in a short non-coding regulatory region (or D-
loop) containing promoter sequences for heavy and light strand transcription 
and origin of replication for the heavy strand.  
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MtDNA encodes 13 polypeptides of OXPHOS, 22 tRNA molecules and 12S 
and 16S rRNAs of mitochondrial translation machinery (Anderson, 1981; 
Falkenberg, 2018) (Figure 3). Only a minority of OXPHOS polypeptides and 
mitochondrial translation machinery, that altogether involve hundreds of 
proteins, are therefore encoded by the mitochondrial genome. The rest of the 
genes encoding mitochondrial proteins, including all subunits of Complex II, 
have translocated to the nuclear genome (Timmis, 2004), or were acquired 
during evolution to be part of OXPHOS complexes, mitoribosome, or their 
assembly. The reason for maintaining separate mtDNA genomes, requiring 
dual control of the mitochondrial energy metabolism, remains unclear. 
 
Figure 3 Genes encoded by human (and mouse) mtDNA. Examples of two common mtDNA 
disease mutations have been indicated. Abbreviations: Black genes with capital 
letters indicate the single-letter amino acid code of the corresponding tRNA, 
ND(x)=Complex I subunits, Cyt b=Complex III subunit, CO(x)=Complex IV 
subunits, ATPase(x)=Complex V subunits. Note that none of the Complex II 
subunits are encoded by the mtDNA. 
MtDNA is packed and organized into nucleoprotein complexes, called 
nucleoids. By super-resolution fluorescent microscopy, nucleoids have been 
shown to associate tightly with cristae formations of the inner mitochondrial 
membrane, and to consist mainly of a single mtDNA molecule and TFAM 
proteins (Brown, 2011; Kukat, 2011). TFAM (mitochondrial transcription 
factor A) is a mammalian mtDNA-associated protein that coats and packages 
mtDNA in a histone-like manner, and bends the promoter to allow 
transcription (Fisher, 1992). Experimental models have shown robust 
dependence of mtDNA stability and amount on TFAM expression levels 
(Larsson, 1998; Ekstrand, 2004). The role of the replication machinery and 
other proteins influencing mtDNA stability are discussed later in chapters 2.3 
and 2.4.2.  
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Depending on the tissue type, each cell carries a large amount of mtDNA 
copies, from tens to several thousands of mtDNA molecules. If all mtDNA 
molecules are identical, the state is called homoplasmy. However, if e.g. 
mutated and healthy mtDNA molecules co-exist, the state is heteroplasmic. 
Many diseases have been reported to manifest only after a critical threshold of 
mutant mtDNA heteroplasmy level (Taylor, 2005). The mechanisms through 
which the cells can regulate the level of heteroplasmy or select between 
mtDNA molecules are not completely understood. In diseases, as well as in 
specific tissue environments and cell culture conditions, however, certain 
mitochondria and/or mtDNA haplotype have been shown to be selected for or 
against (Jenuth, 1997; Jokinen, 2013, 2016). For example, in stem cells, 
mitochondria have been reported to asymmetrically distribute between 
daughter cells to maintain stemness of the one receiving young mitochondria 
(Katajisto, 2015).  
In reproduction, mtDNA follows uniparental transmission. In mammals, 
mitochondria of the sperm cells are actively degraded in the oocyte (Sato, 
2013). Therefore, the mitochondria of the mother give rise to mitochondrial 
population of the progeny, with implications on the inheritance patterns of 
genetic mitochondrial diseases (Taylor, 2003) forensic sciences and 
anthropology. Evidence of paternally transmitted mtDNA in human pedigrees 
has been reported as a rare occurrence (Schwartz, 2004; Luo, 2018) but 
whether such mechanisms truly occur is still under debate in the 
mitochondrial genetics field, and the phenomenon is unlikely to have a major 
contribution in mitochondrial inheritance (McWilliams, 2019).  
2.3 FUNCTIONAL OXPHOS AS RESULT OF 
SUCCESSFUL MITOCHONDRIAL PROTEIN 
SYNTHESIS  
Mitochondria have their own protein synthesis machinery devoted to 
synthesize the mtDNA encoded OXPHOS subunits. The synthesis of these 13 
mtDNA encoded polypeptides is completely dependent on and regulated by 
nuclear encoded proteins that maintain and express mtDNA (Suomalainen, 
2018). See Figure 4 for simplified representation of the steps and some key 
proteins involved in expression of the mtDNA. 
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Figure 4'  Overview of the 
mitochondrial protein 
synthesis and mtDNA 
maintenance, essential for 
functional OXPHOS assembly. 
Abbreviations: 
ANT1=mitochondrial 
ADP/ATP translocase 1, 
DGUOK=deoxyguanosine 
kinase, mtSSBP= 
mitochondrial single strand 
binding protein, 
POLG=polymerase gamma, 
POLRMT=mitochondrial RNA 
polymerase, RRM2B= 
ribonucleotide reductase 
regulatory TP53 inducible 
subunit M2B, TFAM= 
mitochondrial transcription 
factor A, TK2=thymidine 
kinase 2, TYMP=thymidine 
phosphorylase.  
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MtDNA can be replicated independently of cell cycle, even in post-mitotic cells 
(Clayton, 1982). Mitochondrial DNA replication is carried out by specialized 
enzymes, distinct from the nuclear DNA replication machinery. The minimal 
replisome of mtDNA (in vitro) consists of polymerase gamma (POLG, ! and " 
subunits), helicase TWINKLE and mitochondrial single strand binding 
proteins (mtSSBP) (Korhonen, 2004). The POLG has been thought to be the 
primary and only replicative polymerase and DNA repair enzyme in 
mitochondria (Bolden, 1977). However, increasing evidence during the last 
decade shows that alternative polymerases may also localize to mitochondria 
(Krasich, 2017). These polymerases have not been shown to have a major 
contribution in basal replication but could become essential during damage or 
stress related conditions. For example, PrimPol has been shown to assist re-
priming of DNA replication after mtDNA damage (Stojkovi!, 2016; 
Torregrosa-Muñumer, 2017). The TWINKLE helicase was originally found in 
a study that described a novel disease-causing mutation for PEO (see 2.4.2.2). 
The mammalian TWINKLE is homologous to the bacteriophage T7 gene 4 
helicase/primase, but the mammalian enzyme is likely to only possess the 
DNA unwinding helicase function in the replicative fork (Spelbrink, 2001), 
while the mitochondrial RNA polymerase serves as the primase (Wanrooij, 
2008). MtSSBP binds and protects single stranded mtDNA from nucleases 
and secondary structure formation, and functionally enhances POLG and 
TWINKLE processivity (Mignotte, 1985; Tiranti, 1995; Farr, 1999; Korhonen, 
2003).  
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In the context of tissues in vivo, numerous additional to the minimal 
replisome proteins are known to regulate mtDNA maintenance. For example, 
mutations in OPA1 of mitochondrial fusion machinery cause mtDNA deletions 
(Amati-Bonneau, 2008; Hudson, 2008). Importantly, the replication and 
transcription of mtDNA are dependent on nucleotide availability. As mtDNA 
synthesis in continuous and occurs irrespective of the cell cycle in post-mitotic 
tissues, the salvage pathways of nucleotide synthesis in mitochondria are 
considered particularly important for mtDNA maintenance. Both cytoplasmic 
and mitochondrial dNTP pool regulation, and adenine nucleotide 
transportation, have been shown to be essential for mtDNA maintenance 
(Nishino, 1999; Kaukonen, 2000; Mandel, 2001; Saada, 2001; Fratter, 2011).  
Alternative models of replication for the mtDNA have been described. The 
understanding is not complete and several modes may co-exist simultaneously 
(Holt, 2000, 2012). The first described and widely accepted strand-
displacement model of mtDNA synthesis is asymmetric, originating from 
separate heavy and light strand replication origins (Robberson, 1972; Clayton, 
1982). In the strand-displacement model, replication initiates first from the 
heavy strand origin of replication (OH), located in the non-coding regulatory 
region of mtDNA. Replication of the leading strand from the OH proceeds 
approximately two thirds of the mtDNA length until it reaches the light strand 
origin of replication (OL). When the OL is exposed, the lagging strand 
replication then proceeds to the opposite direction. RNA primers are needed 
for initiation of synthesis to start from OH and OL, synthesized by the 
mitochondrial RNA polymerase (POLRMT) (Xu, 1996; Wanrooij, 2008). In 
another mechanism, very similar to strand-displacement model, replication of 
the leading strand exposes the lagging strand for incorporation of RNA-
intermediates that are subsequently replaced by, or converted to, DNA 
(Yasukawa, 2006). This RITOLS (RNA incorporated throughout the lagging 
strand) model implies that synthesis of both strands is asymmetric and 
uncoupled, but the main difference to the strand-displacement model is 
protection of not-replicated strand with RNA rather than mtSSBP. 
Furthermore, also a strand-coupled synthesis model has been described, 
where synthesis of both strands is simultaneous and symmetrical. The strand-
coupled mode of replication was found alongside the other modes and likely 
utilized by the cell under certain conditions that require robust synthesis of 
new mtDNA molecules (Holt, 2000).  
2.3.2 MITOCHONDRIAL GENE EXPRESSION 
Central dogma of molecular biology implies transfer of information in 
sequential steps: DNA-encodes information to make mRNA (transcription), 
mRNA-code matches amino acids that form polypeptides (translation), 
further folded into functional proteins. The mitochondrial gene expression 
(transcription of mtDNA and mitochondrial translation) system shares 
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features of the bacterial origin, but is not completely analogous to either the 
prokaryotic or eukaryotic cytoplasmic processes.  
Transcription of mtDNA originates from the non-coding region containing 
the heavy and light strand promoters (Chang, 1984). MtDNA is transcribed by 
the mitochondrial RNA polymerase (POLRMT) (Tiranti, 1997) and produces a 
long polycistronic mRNA, similar to prokaryotes. The polycistronic mRNA is 
processed by cleavage enzymes, allowing further modifications of mRNA and 
folding of tRNA molecules to secondary and tertiary structures (Hällberg, 
2014).  
During translation, the mRNA is read in three-base codons by the mito-
ribosomes. Each codon codes for an amino acid, START or STOP signal. The 
mitochondrial genetic code differs from the eukaryotic cytoplasmic code and 
is initiated exclusively with a formylated methionine, similar to bacterial 
translation (Hällberg, 2014). During the elongation phase of translation, each 
codon has a cognate mitochondrial encoded tRNA that brings the correct 
amino acid to the reaction. Mt-tRNAs, in turn, are aminoacylated by nuclear 
encoded mitochondrial aminoacyl-tRNA synthetases, mt-aaRS (Konovalova, 
2013).  
Synthesis of polypeptides by mitoribosomes takes place on the inner 
mitochondrial membrane. The mitoribosome has the traditional ribosome 
structure that consists of large and small subunits but has exceptionally high 
protein to rRNA ratio. In the translation process, numerous nuclear encoded 
initiation-, elongation- and termination factors are involved. The synthesis of 
the nascent OXPHOS polypeptides in mitochondria appears to be 
simultaneous to membrane insertion and folding, involving specialized 
assisting machineries and active quality control. (Hällberg, 2014; 
Suomalainen, 2018). 
 
2.4 MITOCHONDRIAL DISEASES 
2.4.1 SPECTRUM OF CLINICAL AND GENETIC DEFECTS 
According to the current listings, 250-300 mitochondrial proteins are 
reported to carry disease-causing mutations. The most recent update of 
proteins located to mitochondria is around 1200 (Calvo, 2016), expanding the 
list of possible disease causing candidate genes. The most common 
mitochondrial diseases involve compromised function of OXPHOS. Even 
under the “OXPHOS umbrella”, however, mitochondrial diseases are clinically 
an exceptionally variable group of disorders. Therefore, individual disorders 
are rare, the rarest ones sometimes only described in a few pedigrees. If 
combined, however, estimates based on European populations state that 
prevalence of mitochondrial disease could be 1/4000, making them one of the 
most common inherited neurological or metabolic disorders (Gorman, 2015; 
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Saneto, 2017). The reason for the clinical diversity is poorly understood and 
mitochondrial diseases are currently mostly lack a cure. In summary, classical 
features of mitochondrial diseases (some of them are listed next to the 
symptoms in the illustration below) are summarized by the following 
statements (modified from Ylikallio, 2012; Ahmed, 2018):  
 
   
 
The subsequent chapters introduce the clinical, genetic and molecular 
characteristics of the relevant mitochondrial diseases for this thesis. The 
diseases are divided into sub-groups according to the molecular nature of the 
genetic defect, all fundamentally compromising the function of OXPHOS. 
First, mutations that directly affect structure or assembly of the respiratory 
chain complexes are introduced. Second, mechanisms that compromise 
maintenance and expression of mtDNA are discussed.  
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Clinically, respiratory chain mutations manifest early in life as severe 
neurological diseases. Biochemical assessment of tissue samples may reveal 
isolated complex deficiency. As mtDNA encodes only 13 polypeptides of the 
OXPHOS, nuclear mutations of the structural subunits of the catalytic cores 
and their assembly factors outnumber the mitochondrial mutations.  
One example of a primary OXPHOS disease is Leigh or Leigh-like 
syndrome, also called ‘Leigh disease or subacute necrotizing 
encephalomyelopathy’ (OMIM entry #256000) (Leigh, 1951). Leigh syndrome 
is a classical mitochondrial disease, manifesting typically before two years of 
age with progressive symptoms, and having various genetic causes. Variable 
neurological symptoms in Leigh (for example psychomotor retardation, 
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hypotonia, ataxia, seizures) arise from specific bilateral lesions in the basal 
ganglia and thalamus, and associated abnormalities. Although the 
neurological symptoms dominate the clinical description of Leigh disease, 
skeletal muscle may show OXPHOS deficiency, and a biopsy sample can be 
used for diagnostic assays of mitochondrial function and mtDNA. Mutations 
in nuclear-encoded mitochondrial proteins for Complex I, II, III, or IV, 
mtDNA-encoded subunits of the ATP synthase and respiratory chain complex 
assembly factors are the main genetic causes of early onset Leigh disease. More 
rare causes involve defects of Coenzyme Q10 metabolism or the TCA cycle 
enzymes (Baertling, 2014; Rahman, 2017). 
2.4.1 MITOCHONDRIAL TRANSLATION DISORDERS 
In biochemical assays, protein synthesis diseases usually manifest as 
generalized OXPHOS deficiency of single or multiple organs. Of the numerous 
mitochondrial protein synthesis factors, almost all are described with disease-
causing mutations. However, defects in mitochondrial tRNAs and nuclear 
encoded mt-aaRSs are the most prevalent causes of mitochondrial protein 
synthesis diseases (Suomalainen, 2018). 
MELAS (OMIM entry #540000), or Mitochondrial myopathy, 
encephalomyopathy, lactic acidosis, and stroke-like episodes syndrome, is 
almost exclusively caused by m.3243A>G point mutation on mtDNA encoded 
MT-TL1 gene (encoding for mitochondrial tRNALeu) (Goto, 1990) (Figure 3). 
MELAS manifests as a complex multi-organ disease where most frequent 
clinical findings are strokes, epilepsy and exercise intolerance combined with 
finding of ragged red muscle fibers (excess proliferation mitochondria, a 
histological hallmark of mitochondrial disease) (El-Hattab, 2015). 
Surprisingly, mutations in different mitochondrial tRNA molecules do not 
cause similar diseases (Blakely, 2013). MERRF (OMIM entry #545000), or 
myoclonus epilepsy and ragged red fibers, is predominantly caused by 
m.8344A>G mutation in mitochondrial MT-TK gene of tRNALys (Shoffner, 
1990), but is clinically distinct from MELAS with more restricted 
manifestation with seizures and myopathy, and shows a peculiar phenotype of 
symmetric lipomas in the neck-shoulder region. The different manifestations 
may arise from the different nature of defects in the protein synthesis 
machinery and the subsequent quality control needed for resolving the 
damage (Battersby, 2019), as well as tissue-specific demands and remodeling 
of metabolism. Furthermore, the prevalent m.3243A>G point mutation not 
only causes MELAS but also a spectrum of disorders and manifestations with 
variable severity, for example maternally inherited diabetes and deafness 
(MIDD) (van den Ouweland, 1994), PEO, mitochondrial myopathy, 
cardiomyopathy, migraine or cognitive impairment (Nesbitt, 2013). This 
spectrum of clinical manifestations for m.3243A>G has been shown to present 
poor correlation with heteroplasmy level, age or sex, although the heritability 
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of subset of symptoms are higher, suggesting strong modification by the 
nuclear background (Pickett, 2018).  
In addition to mtDNA tRNA mutations, essentially all nuclear encoded mt-
aaRS have been described with pathogenic mutations that are expected to 
impair mitochondrial protein synthesis (Konovalova, 2013; Sissler, 2017). The 
main clinical manifestation is often early-onset encephalopathy, but the 
spectrum of clinical manifestations ranges from cardiomyopathy to hearing 
loss, infertility, hematologic manifestations, and adult-onset myopathy 
(Konovalova, 2013; Suomalainen, 2018). The variable tissue specificity could 
be explained by unconventional non-translational activity of the mt-aaRS, 
already described for many of the cytoplasmic amino acid synthetases (Guo, 
2013), but not yet for mammalian mt-aaRS (Tyynismaa, 2014). However, in 
yeast, overexpression of non-catalytic domain of mt-LeuRS was able to 
suppress growth retardation caused by the cognate mt-tRNA ablation, and 
similar results have been published for mammalian cells with the m.3243A>G 
mutation (Park, 2008; Francisci, 2011). Moreover, a human subject with 
pathogenic mt-tRNAIle mutation remained clinically unaffected because of 
naturally higher expression level of mt-IleRS (Perli, 2012). Therefore, these 
evidence from both mt-tRNA and mt-aaRS diseases points to yet 
uncharacterized levels of regulation in mitochondrial translation and cellular 
amino acid metabolism, with implications on clinical manifestation.  
2.4.2 MTDNA MAINTENANCE DISORDERS 
Defects in mtDNA maintenance machinery can lead to pathological mutations, 
namely deletions or depletion of mtDNA. The causative genes for mtDNA 
depletion and deletion syndromes almost completely overlap but clinical 
presentations are often remarkably different, forming a clinical continuum 
with the manifestation depending on the age of onset of the disease.  
In simple terms, mtDNA depletion syndromes are usually recessively 
inherited infantile-onset diseases that manifest with either hepatocerebral, 
neuro-gastrointestinal, encephalomyopathic or myopathic set of symptoms. 
Mutations in genes regulating the nucleotide pools and mtDNA replication 
compromise mtDNA maintenance and cause mtDNA depletion (El-Hattab, 
2013). Yet, the most common single gene for mtDNA depletion syndromes is 
POLG, a leading cause of childhood-onset neurological disorders of 
mitochondrial origin, such as Alpers-Huttenlocher syndrome (Naviaux, 2004; 
Suomalainen, 2010; El-Hattab, 2013). Hepatocerebral manifestation due to 
mtDNA depletion is frequently caused by recessive mutations in 
deoxyguanosine kinase, or the replicative helicase TWINKLE, the latter 
manifesting as infantile-onset spinocerebellar ataxia syndrome, IOSCA 
(Nikali, 2005; Hakonen, 2008). Only recently, the third player of mtDNA 
minimal replisome, mtSSBP, was described with dominant and recessive 
mutations underlying multi-tissue mtDNA depletion in an optic atrophy 
disorder with kidney failure (Del Dotto, 2019).  
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MtDNA deletions can occur spontaneously, causing diseases without 
known involvement of mitochondrial or nuclear genes. The single deletions of 
mtDNA are typically sporadic in nature and occur early in the embryonic 
development (Marzuki, 1997). Most common single deletion associated with 
PEO (and Kearns-Sayre and Pearson syndromes) is 4977 base pairs in length, 
flanked by 13-base-pair direct repeats. The repeats have been proposed to 
predispose the replisome for slipping and mispairing the template, thereby 
generating the deletion. The mtDNAdel4977 removes four genes for subunits of 
Complex I, one gene for Complex IV, two genes for Complex V, and five genes 
for tRNAs (Shoffner, 1989) (Figure 3). In addition to sporadic deletions, 
mutations of the mtDNA maintenance factors (see Figure 4 and 2.3.1) cause a 
spectrum of adolescence or adult-onset ataxia syndromes or pure myopathies 
that are rather characterized by multiple mtDNA deletions (Spelbrink, 2001; 
Hakonen, 2005; Winterthun, 2005). The mechanisms of how mtDNA 
replication defects cause tissue-specific manifestations are not known, and 
may involve secondary genetic and environmental modifiers. Interestingly, 
POLG expression has been suggested to be regulated by a set of central 
nervous system specific complex enhancers and regulatory RNA species, 
offering new genomic insight for explaining the mechanisms of tissue specific 
manifestations (Nikkanen, 2018). 
In this thesis, we have focused our studies on patients with AdPEO (OMIM 
entry #609286, PEOA3, AdPEO, PEO), caused by sporadic single mtDNA 
deletions or secondary multiple mtDNA deletions due to TWINKLE mutation. 
For AdPEO-like progressive multiple deletions and mitochondrial myopathy, 
a corresponding mouse model, Deletor, has been described in laboratory of A. 
Suomalainen-Wartiovaara (Tyynismaa, 2005, 2010). The clinical and 
molecular pathology of the PEO patients and Deletor mouse is described in the 
following chapters. 
2.4.3 MITOCHONDRIAL MYOPATHY CAUSED BY MTDNA 
DELETIONS: ADPEO AND DELETOR MOUSE   
Clinically, AdPEO patients manifest an adult-onset slowly progressive 
myopathy with extra-ocular muscle weakness and ptosis, combined with 
generalized exercise intolerance (Lewis, 2002) and sometimes psychiatric 
symptoms (Suomalainen, 1992).  TWINKLE mutations were described as the 
underlying cause of the multiple mtDNA deletions in early 2000s (Spelbrink, 
2001) but presence of the multiple deletions up to seven kilobases in size were 
already described earlier in muscle and brain of PEO patients (Holt, 1988; 
Yuzaki, 1989; Zeviani, 1989; Suomalainen, 1992, 1997). The deletions were 
frequently found to originate from the D-loop region with susceptibility to 
generation of fragments flanked by short repeats (Schon, 1989; Zeviani, 1989), 
similarly to single mtDNA deletion patients. Interestingly, these pedigrees 
showed autosomal inheritance of the diseases, indicating a nuclear gene 
causing mtDNA deletions, and later identified as being caused by mutations in 
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mtDNA maintenance proteins (Suomalainen, 1995; Nishino, 1999; Kaukonen, 
2000; Spelbrink, 2001). 
On molecular and biochemical level, the large-scale deletions of mtDNA 
compromise function of several subunits of OXPHOS complexes as well as 
mitochondrial tRNAs, manifesting as multicomplex respiratory chain 
dysfunction. The respiratory chain dysfunction in the affected muscle can be 
detected as cytochrome c oxidase (COX) negative fibers. The COX-negative 
fibers often show characteristic accumulation of mitochondria (modified 
Gomori trichrome staining of the nuclear encoded Complex II), called ragged 
red fibers (RRF or SDH positive fibers). (See Figure 17 for examples of COX-
negative and SDH-positive muscle fibers). Ultrastructure of the mitochondria 
in the affected fibers is often compromised and electron microscopy reveals 
large, hypodense mitochondria with disorganized cristae and different 
inclusion bodies (Suomalainen, 1992; Tyynismaa, 2005; Vincent, 2016). 
The Deletor mouse model of mitochondrial myopathy carries a 
corresponding mutation to certain AdPEO patients, a 39-bp duplication in 
murine Twinkle cDNA, causing an in-frame duplication of 13 amino acids 
(353–365) in Twinkle (=Twinkledup353-365). The Twinkledup transgene is 
expressed under a ubiquitous β-actin promoter, but the expression of mutant 
versus wild-type Twinkle is maximally 1:1, mimicking the situation in the 
autosomal dominant disease (Tyynismaa, 2005). The duplication locates in 
the linker domain of Twinkle. This mutation does not affect the Twinkle 
hexamer formation, but affects the helicase structure, causing occasional 
replicative fork stalling that may predispose mtDNA to deletion formation 
(Goffart, 2009).  
The Deletor mouse was one of the first mouse models for mitochondrial 
diseases that accurately mimicked disease hallmarks seen in human patients. 
Deletor mouse findings resemble closely the findings in the PEO patients that 
carry the same mutation, on genetic, histological and biochemical levels. The 
mice manifest with progressive mtDNA instability and late-onset respiratory 
chain deficiency in the skeletal muscle, heart and distinct neuronal 
populations (Tyynismaa, 2005). Therefore, the Deletor has been useful in 
studies tackling the mechanisms of pathophysiology and stress responses, the 
main topics of all original publications in this thesis.  
The biochemical and molecular pathogenesis of the Deletor mouse is well-
characterized (Tyynismaa, 2010; publications of this thesis), and the model 
has proven to be useful in treatment studies (Ahola-Erkkila, 2010; Yatsuga, 
2012; Khan, 2014), out of which some have been subsequently applied in pilot 
clinical trials on patients (Ahola, 2016). The treatments have relied on dietary 
interventions and co-factor supplements designed to resolve the metabolic 
roadblocks caused by mitochondrial respiratory chain dysfunction in the 
muscle. For example, NAD-deficiency was found to occur as a consequence of 
mitochondrial myopathy in these mice, and supplementation with a precursor 
of NAD, B3-vitamin nicotinamide riboside (NR), was able to restore the 
shifted balance of NAD+/NADH. NR-treatment led to a marked increase in 
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mitochondrial biogenesis and rescued pathological findings in muscle of 
Deletor mice (Khan, 2014). This approach has also been applied in another 
mitochondrial disease model (Cerutti, 2014) and reported to alleviate general 
age-associated physical decline (Mills, 2016). Vitamin-B supplements are 
suggested to be safe and efficient in human subjects even in large doses 
(Conze, 2019) and several pilot clinical trials on those are ongoing in 
mitochondrial diseases (www.clinicaltrials.gov and personal communication). 
Boosting of ketone body oxidation is another metabolic treatment that some 
mitochondrial disease patients have benefited from, especially in epileptic 
manifestation caused by OXPHOS deficiency (Kang, 2007). Pathological signs 
in muscle of Deletor were improved after consumption of ketogenic diet pre-
and post-symptomatically (Ahola-Erkkila, 2010). Mitochondrial myopathy 
patients responded to a low carbohydrate ‘modified Atkins diet’ with subacute 
muscle fiber damage specifically affecting the most sick muscle fibers and 
long-term effects showed slight improvement of muscle function (Ahola, 
2016). These examples demonstrate the major effects of diet and vitamins as 
modifiers of metabolic roadblocks with potential to alleviate consequences of 
mitochondrial dysfunction. Furthermore, the examples underline the 
usefulness of pre-clinical models parallel to patient studies for rare diseases, 
although the inter-species differences in responses need to be considered.  
2.5 FGF21 – A CIRCULATING BIOMARKER WITH 
METABOLIC CONSEQUENCES 
2.5.1 STRESS SIGNALING AND CONCEPT OF SYSTEMIC 
ADAPTATION TO LOCAL MITOCONDRIAL DYSFUNCTION 
In Deletor mouse, a chip-transcriptomic analysis of the affected muscle led to 
identification of a specific group of genes that carry a shared sequence in their 
promoter region, namely the amino acid response element (AARE) 
(Tyynismaa, 2010). The AARE-motif is known to be bound by the activating 
transcription factor (ATF) family of transcription factors responsive in stress 
conditions such as starvation (Stevenson, 2005; Nargund, 2012). Later on, this 
transcriptional response was demonstrated to be downstream of mTORC1 
(mechanistic target of rapamycin complex 1), a major regulator of anabolic 
metabolism (Laplante, 2012; Khan, 2017). Interestingly, among the 
upregulated transcripts of Deletor muscle were two secreted factors, 
Fibroblast growth factor 21 (FGF21) and Growth and differentiation factor 15 
(GDF15). Both proteins have thereafter been described as specific and 
sensitive serum biomarkers for mitochondrial diseases (Suomalainen, 2011; 
Yatsuga, 2015).  
At the time when it was first linked to mitochondrial disease, FGF21 was 
reported as a metabolic regulator of systemic carbohydrate and fatty acid 
metabolism, described in detail in subsequent chapters. This indicated that 
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mitochondrial dysfunction in one tissue could mediate systemic adaptation of 
the whole organism (Figure 5). A similar concept of such ‘mitohormesis’ soon 
followed also in a C. elegans model of mitochondrial dysfunction (Durieux, 
2011): upon inactivation of mitochondrial cytochrome c oxidase in neuronal 
cells of the worm, these cells initiated a protective local mitochondrial 
unfolded protein response, but the response was also found to occur in the gut 
of the worm where no primary defect occurred. Therefore, a hypothesis was 
put forward that a “mitokine” was secreted from the neurons, eliciting the 
mitochondrial unfolded protein responses (UPRmt) in distant tissues (Durieux, 
2011; Nargund, 2012). Later on, the mitokine of the worm was reported to be 
a Wnt-ligand/EGL-20, expressed under activation of ATFS-1 transcription 
factor that promotes AARE-regulated transcription of mitochondrial heat 
shock proteins (Nargund, 2012; Zhang, 2018). The relevance of this worm 
response in mammals has so far not been clarified.  
 
Figure 5' The ‘Mitokine’ hypothesis presented for FGF21 in mammals, the central hypothesis 
of this thesis. FGF21 expression and secretion from skeletal muscle correlate with 
severity of respiratory chain deficiency in Deletor muscle. Systemic exposure to 
hormone FGF21 potentially regulates systemic adaptation and metabolism in 
response to the restricted tissue-specific disease manifestation. 
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(Kharitonenkov, 2005). In humans, a prolonged (seven days) fasting was 
reported to cause FGF21 secretion (Muise, 2008). In fasting, FGF21 is 
expressed in response to peroxisome proliferator-activated receptor a 
(PPARa) activation (Badman, 2007, 2009; Inagaki, 2007; Lundasen, 2007; 
Potthoff, 2009). PPARs are nuclear receptor transcription factors that get 
activated under conditions of energy deprivation, promoting catabolism of 
fatty acids and supporting ketogenesis (Kersten, 1999). Importantly, the 
PPARa-mediated production of ketone bodies in the liver and systemic 
mobilization of fatty acids are shown to be highly dependent on FGF21 
(Kharitonenkov, 2005; Badman, 2007).  
Studies on transgenic and pharmacogenetic models of FGF21 revealed that 
FGF21 is important in regulation of systemic metabolic homeostasis and body 
weight. Excessive FGF21 led to weight loss and resistance to diet-induced 
obesity, and lack of FGF21 predisposed mice to weight gain and metabolic 
syndrome (Kharitonenkov, 2005, 2007; Coskun, 2008; Xu, 2009; Veniant, 
2012). Pharmacological treatment with recombinant FGF21 protein, and 
synthetic variants, was shown to reduce body weight, improve insulin 
sensitivity, boost lipid metabolism and increase energy expenditure in 
rodents, non-human primates and humans (Coskun, 2008; Veniant, 2012; 
Gaich, 2013; Kharitonenkov, 2013; Kim, 2015). Controversially, high levels of 
circulating FGF21 have been reported in humans with obesity, metabolic 
syndrome and fatty liver (Zhang, 2008; Chavez, 2009; Mraz, 2009; Mashili, 
2011; Tyynismaa, 2011), suggesting decreased sensitivity to FGF21, similar to 
insulin-resistant conditions.  
FGF21 was shown to freely pass through the blood-brain barrier in rodents 
(Hsuchou, 2007; Tan, 2011) and injection of recombinant FGF21 to rat 
cerebrospinal fluid increased hepatic insulin sensitivity and metabolic rate 
(Sarruf, 2010), suggesting a regulatory role for FGF21 on metabolism through 
the central nervous system.  Expression of the co-receptor β-Klotho was found 
to be concentrated in hypothalamus, and disturbance of FGF21-β-Klotho 
interaction in the brain impaired the basic FGF21-mediated physiological 
functions (Bookout, 2013; Owen, 2013; Liang, 2014; Yilmaz, 2018; Hill, 2019). 
Since then, nervous system effects of FGF21 have been shown to be important 
in complex regulation of appetite for macronutrients and stimulants, such as 
sugar and alcohol (Schumann, 2016; von Holstein-Rathlou, 2016; Chen, 2017; 
Desai, 2017; Matsui, 2018; Søberg, 2018).  
2.5.3 FGF21 AND NEUROPROTECTION 
Enhanced hepatic ketone production induced by FGF21 can be considered 
neuroprotective in nutrition-poor conditions. Additionally, periphery-derived 
FGF21 was reported to mediate hibernation or torpor-like state in rodents, a 
condition known to preserve and deviate energy for essential basic organ 
functions (Inagaki, 2007; Ishida, 2009). Further studies during the years have 
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revealed a spectrum of detailed functions for FGF21 in protection of the 
nervous system.  
In transcriptional profiling of neuronal cultures exposed to common 
antidepressant and epilepsy drugs, lithium and valproic acid, intrinsic 
expression of FGF21 was induced (Leng, 2015). In that study, Leng et al. 
(2015), proposed that exogenously administered FGF21 prevented glutamate 
induced excitotoxicity and apoptosis in neuronal cultures through activation 
of Akt-1. Notably, FGF21 has been reported to support pancreatic beta-cell 
function via Akt-1 signaling cascades (Wente, 2006). In muscle cells, 
expression of FGF21 is reported to be downstream of Akt-1 (Izumiya, 2008). 
These studies highlighted that FGF21 can be expressed from a variety of 
tissues and act through conserved pathways that promote cell-survival and 
neuroprotection (Chiu, 2010). 
Hyperglycemia-linked pathology in the nervous system has increased 
interest towards periphery driven modifiers of metabolism in the 
pathophysiology of neurodegenerative diseases. Very recently, FGF21 was 
shown to support maintenance of intact blood brain barrier in hyperglycemic 
of diabetic mice (Yu, 2019) and mediate neuroprotective actions through 
activation of cell-to-cell adhesion factor expression in traumatic brain injury 
(Chen, 2018). In another study on cerebral microvascular endothelial cells in 
vitro, FGF21 was shown to reduce apoptosis, alleviate inflammatory response 
and suppress damage by ROS and other hypoxia related pathological 
consequences (Wang, 2019). Protective effects of FGF21 have even been 
studied in a mouse model of Alzheimer’s disease, where it was reported to 
ameliorate tau-aggregation and ROS pathology, thereby providing a 
mechanistic link to the regulation of hypoxia signaling (Chen, 2019). These 
examples highlight the accelerating efforts to unravel mechanisms of FGF21-
mediated neuroprotection, with potential therapeutic opportunities for 
common neurodegenerative conditions that involve direct or secondary 
impairment of mitochondria.  
2.6 METABOLOMICS IN RESEARCH AND 
DIAGNOSTICS OF MITOCHONDRIAL DISEASES 
Secondary metabolic perturbations, up-and downstream of the mitochondrial 
OXPHOS defects, are a poorly understood consequence of mitochondrial 
diseases. Several such changes are however used as biomarkers for disease. 
For example, elevated lactate or increased lactate/pyruvate ratio in blood or 
cerebrospinal fluid are markers of mitochondrial dysfunction (Haas, 2008), 
reflecting also cellular NADH/NAD+ ratio (Nelson and Cox, 2008, chapter 14). 
However, these markers are not raised in all mitochondrial disease. 
Furthermore, for example levels of lactate and pyruvate are also elevated in 
response to other physiological and pathophysiological stimuli such as 
exercise, metabolic crisis and inflammation. Profiling of blood total amino 
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acids or carnitine and acyl-carnitines have been utilized to indicate 
mitochondrial disease. Acyl-carnitine profiling permits identification of 
secondary fatty acid oxidation defects that may occur in primary OXPHOS 
disorders (Haas, 2008) but are also markers of primary fatty acid oxidation 
diseases (Sim, 2002). Several markers of cellular metabolic disturbances have 
therefore been utilized routinely but with limited diagnostic sensitivity and or 
specificity. 
2.6.1 MASS SPECTROMETRIC PROFILING  
Mass spectrometry (MS) is an analytical technique that measures the mass-to-
charge ratio of ionized molecules. Basic parts of a MS are ionizer, mass 
analyzer and detector. Results are presented as a mass spectrum, from which 
the identity of target molecules or isotopic signature of a sample can be 
determined. Several pre-separation techniques of the targets can be combined 
with mass spectrometry. Popular method in biological research is liquid 
chromatography (LC) or high-performance liquid chromatography (HPLC) in 
combination with MS, LC-MS. Liquid chromatography separates complex 
biological samples according to favored chemical or physical properties, 
increasing the sensitivity of the subsequent MS identification (Gohlke, 1959). 
Modern targeted MS methods utilize multiple stages of tandem mass 
spectrometry for ions of specific mass, defined by standard molecules derived 
from previous analyses. This enables (semi) quantitative detection of 1x102 
magnitude of low molecular weight metabolites in a single run, providing 
possibilities for diagnostic use (Nandania, 2018). 
Easily accessible body fluids, serum, plasma and urine, have been used to 
recognize signature patterns of single or multiple metabolite characteristics 
for certain mitochondrial diseases (Buzkova, 2018; Esterhuizen, 2019). 
Metabolic analysis of patient tissues can direct the diagnostic process, but 
better knowledge of the metabolic rearrangements is still required. However, 
knowledge of metabolism has broadened the view on pathophysiological 
mechanisms of mitochondrial diseases and might offer possible therapy 
targets in the future.  
2.6.2 STABLE ISOTOPE LABELING WITH [13C]  
Metabolic flux analysis enables tracking the fate of isotope-labeled substrate 
carbons, reflecting dynamics of metabolism, and giving insight into catabolic 
and anabolic reactions in vivo or in cell cultures. For example, 13C is a naturally 
occurring heavy, non-radioactive, rare isotope of carbon, 12C being the most 
abundant one in nature. Detection of different isotopic atoms in a molecule 
can be done with nuclear magnetic resonance (NMR) or mass spectrometry-
based analyses. Further analysis is based on advanced mathematical solutions 
and advanced computing to understand the metabolic networks. (Wiechert, 
2001; Dai, 2017). 
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A common metabolic flux experiment, tracking nutrient usage, utilizes 
labeled glucose. Glucose can be labeled uniformly for all six carbons, [U-13C]-
glucose, or on definite positions chosen for specific cellular pathways (such as 
glycolysis or the pentose phosphate pathway). The model system, cell culture 
or an animal, is provided with labeled substrate and the fate of labeled element 
is tracked among target molecules. In mass spectrometry, the labeled 
substrates are referred as mass isotopomers, (m+X), X being the number of 
substituted elements in the structure. For example, [U-13C]-glucose can yield 
to wide variety of (m+X) products starting from glycolysis, TCA-cycle and all 
subsequent and branching biosynthetic processes. Rapid metabolic processing 
and numerous fates of universal nutrient molecules make metabolic flux 
analysis technically challenging. Especially the live-cell labeling steps are 
prone to variation through experimental design, handling and biological 
variation, highlighting the need for proper experimental planning and use of 
appropriate controls. (Dai, 2017). 
2.6.3 POSITRON EMISSION TOMOGRAPHY  
Positron emission tomography (PET) is an important quantitative non-
invasive imaging method in medicine. Positron beta emission (β+) derives 
from decay of radionuclides, in which the number of protons exceed the 
number of neutrons. In β+ emission, two positrons are emitted to opposite 
directions, close to 180° angle. In the context of biological systems, such as the 
human body, the positrons annihilate with electrons, releasing two gamma 
particles in the same direction of movement as the original positrons. PET 
scanners detect the gamma-rays (!) that derive from indirect positron 
emission. Two gamma particles arriving to the PET detectors simultaneously 
in 180° angle are recorded. Information from multiple ring-organized is 
integrated to construct a 3D image of annihilation events. In most medical 
PET-scanners, a parallel X-ray based cross sectional computed tomography 
(CT) is overlaid with the PET image for a better spatial reconstruction 
(Dahlbom, 2017) (Figure 6).  
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Figure 6' Left: Schematic illustration of the basic principle of PET imaging. Right: Example 
of a reconstructed PET-image of [18F]-FDG tracer overlaid with a CT scan. Rainbow 
color indicates [18F]-intensity in soft tissues, white skeleton is reconstructed from 
the CT-scan.  
Resolution of PET scanners is limited by the distance the positron travels 
before annihilation event, usually 0.5-8 millimeters (Saha, 2010; Granov, 
2013). This can be a challenge for preclinical studies of small laboratory 
animals, such as mice. In small tissues or body fluid samples, accumulated 
radioactivity during the uptake period can be measured by gamma counters 
where gamma rays from beta decay in tissue interact with a crystal (ex vivo). 
As a result, light is emitted and converted to an electrical signal. The gamma 
counts are corrected for radionuclide decay (half-life and delay) and reported 
as a percentage of the injected dose per gram of tissue (%ID/g) or as an 
injected dose corrected for body weight and radioactivity per gram of tissue 
(SUV, standard uptake value). For samples that need resolution in the scale of 
sub-organ level, an autoradiograph of accumulated emission can be detected 
from planar surfaces. In autoradiography, beta/gamma emission from tissue 
slices is exposed on X-ray film in tight contact with the specimen, and the films 
are scanned for image reconstruction (Zanzonico, 2012). Such applications 
involve different organ-tumor studies, localized uptake of labeled metabolites 
or receptor binding in rodent brain, for example. After the exposure, the 
samples are suitable for subsequent histological analysis (see Figure 15 for and 
an example of an autoradiograph of mouse brain).  
In PET and ex vivo applications, ultra-short-lived radionuclides are used 
with half-lives ranging from a couple of minutes to hours. Short-lived nuclides 
are produced by radiochemical laboratories with cyclotrons that bombard the 
target substance with an accelerated, charged particle beam. Radio-isotopes of 
carbon (11C), nitrogen (13N), oxygen (15O) and fluoride (18F) are frequently used 
beta emitters with a short half-life. The radionuclides are chemically linked to 
biological or drug-based ligands responsible for targeting of the emitters. In in 
vivo studies, each radiotracer also has a biological half-life, based on the 
metabolic properties of the carrier/ligand in the body (such as fecal and 
urinary excretion or perspiration) (Saha, 2010; Granov, 2013).  
3D-constructed [18F]-FDG PET/CT (mouse)
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In tumor imaging and metabolic activity recordings, glucose analog [18F]-
FDG is the most widely used tracer. The [18F]-FDG, or [2-deoxy-2-(18F)fluoro-
D-glucose], has radionuclide 18F substitution of a hydroxyl group (OH) at the 
C2 carbon of the glucose molecule (Figure 7). Substitution of the OH-group 
with 18F makes the labeled glucose molecule detectable in PET, and prevents 
further metabolism after the first irreversible phosphorylation step of 
glycolysis by hexokinase/glucokinase. [18F]-FTHA, or [14-(R,S)-18Fluoro-6-
thia-heptadecanoic acid], is a mimetic of long chain fatty acids (Figure 7). 18F 
at carbon C14 enables detection and sulfur substitution on the carbon C6 
causes metabolic trapping of FTHA after initial commitment to the beta-
oxidation pathway but FTHA can undergo intracellular and extracellular 
reactions of fatty acid pools (Takala, 2002; Ci, 2006; Guiducci, 2007; Croteau, 
2016). 
   
Figure 7 Chemical structures and modifications of glucose and palmitic acid analogs, [18F]-
FDG and [18F]-FTHA radiotracers, respectively. Numbers indicate atoms of the 
carbon or carbon/sulfur backbone.  
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3 AIMS OF THE STUDY 
The general aim of this thesis was to characterize the metabolic alterations and 
pathophysiology of mitochondrial dysfunction with special emphasis on the 
effects of the metabolic hormone FGF21. Specific aims were as follows:  
 
 
1. To characterize in detail the metabolic remodeling of the affected 
muscles in mitochondrial disease caused by mtDNA instability 
 
2. To clarify the local and systemic effects of chronic exposure to the 
hormone FGF21 on the pathophysiology  
 
3. To examine the diagnostic use and mechanism of induction for FGF21 
(and GDF15) in different mitochondrial diseases 
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4 MATERIALS AND METHODS  
All method details are presented in the original publications and briefly 
described here.  
4.1 ETHICAL STATEMENTS AND LICENSES 
The Ethical Review Board of Helsinki University Central Hospital approved 
the sample collection and analysis of patients and controls, who gave their 
written informed consent, according to the Declaration of Helsinki. Human 
subjects were recruited to studies and sampled in the Helsinki University 
Central Hospital, and part of the samples in study III were obtained from 
international collaboration centers. The National Animal Review Board and 
regional State Administrative Agency for Southern Finland approved the 
animal studies of this thesis and experiments were performed following the 
European Union Directive. 
4.2 MOUSE MODELS  
Deletor mice with a comprehensive FGF21 knockout were generated for this 
study by sequential crosses with existing transgenic mouse lines. 
Heterozygous Twinkledup 353-365 (Deletor) males and PGK-Cre females 
(Lallemand, 1998) were crossed with Fgf21LoxP/LoxP animals (Potthoff, 2009). 
The (Deletor x Fgf21LoxP/LoxP) males were then crossed with (PGK-Cre x 
Fgf21LoxP/LoxP) females. All genotypes were born in the expected Mendelian 
ratios and were viable until euthanasia at 22-24 months of age. The population 
was maintained with crosses between Deletor-FKO males and FKO females. 
Additionally, six previously characterized transgenic and knockout mouse 
models were obtained through collaboration (phenotype of the mice is 
described in section 5.7). Sample collection, preservation and shipping 
conditions were harmonized and analyses were performed in Biomedicum 
Helsinki according to materials and methods. 
4.3 TISSUE COLLECTION 
Mice were euthanized with gradual inhalation of excess carbon dioxide. Post-
mortem blood collection through heart puncture was performed and tissues 
collected within 5-15 minutes of death of the mouse. The collected tissues were 
snap frozen in liquid nitrogen and stored at -80°C, or processed for 
histological analyses as described in methods. 
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4.4 IN VIVO UPTAKE ASSAYS OF 18F-LABELED 
GLUCOSE AND FATTY ACID ANALOGS 
Prior to all tracer uptake assays, food was removed from cages three hours 
before. For fasting experiments, food was removed at 7-9 pm and the uptake 
assay performed the next morning, after 24 hours of fasting. For exogenous 
FGF21 treatment experiment, animals were injected (intraperitoneally) with 
0.06 mg/kg of recombinant mouse FGF21 or saline four hours prior to the 
tracer assay. (See production of r-FGF21 in original publication I.)  
Assays were performed in isoflurane inhalation anesthesia and body 
temperature was controlled with heating pads. The tracers [18F]-FDG or [18F]-
FTHA were injected to the tail vein in total activity of 5 MBq. PET/CT scans 
were performed with Inveon multimodality PET/CT machinery (Siemens). 
Standard uptake values (SUV) (Deleye, 2016) were calculated from 
reconstructed PET images (Inveon Research Workplace visualization 
program, Siemens), or by using a manual gamma counter measurement of 
emitted gamma rays from excised tissues. Quantitative phosphor imaging 
autoradiography of brain was performed on coronal brain cryosections (20 
µm) exposed on an imaging plate (Fuji BAS-TR2025) for approximately 3.5 
hours. The plates were scanned with a Fuji BAS-5000 Phosphor imager and 
signal densities (photostimulated luminescence per unit area, PSL/mm2) 
obtained with an AIDA image analyzer.  
4.5 IN VIVO [U-13C] GLUCOSE FLUX 
For in vivo tracking of glucose 0.7 mg/g dose of [U-13C]-glucose (Cambridge 
Isotope laboratories, CLM-1396) was administered to the mice via tail vein. 
The mice were sacrificed and tissues collected after 5, 10 and 15 minutes of 
uptake. The samples were frozen and the metabolome analyzed by targeted 
selected reaction monitoring liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) on Agilent 6460 QQQ.  
4.6 CELL CULTURE 
All cells were maintained in a humidified chamber at 37°C in 5% CO2. Culture 
conditions involved nutrient rich Dulbecco’s Modified Eagle’s Medium DMEM 
(Sigma-Aldrich), supplemented with fetal bovine serum, pyruvate, 
penicillin/streptomycin and uridine, in presence or absence of actinonin for 
mitochondrial translation inhibition (up to 24 hours). Gene silencing in 
fibroblasts was performed using using the Polyplus jetPRIME transfection kit 
and SilencerSelect (ThermoFisher) siRNAs against scramble control, ATF3, 
ATF34 and ATF5. 
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4.7 QUANTITATIVE REAL-TIME PCR  
RNA was extracted by standard Trizol-chloroform precipitation. Briefly, 
frozen tissue (20 mg in 1 ml of Trizol reagent) was homogenized with the Fast-
Prep w-24 Lysing Matrix D (MP Biomedical) and Precellys w-24 (Bertin 
Technologies). One microgram of RNA was DNase digested and reverse 
transcribed (Maxima first strand synthesis kit). Quantitative PCR 
amplification was performed with the IQ SybrGreen kit (Bio-Rad) on the 
CFX96 Touch qPCR system (Bio-Rad). The relative expressions of genes of 
interest were normalized to the level of β-actin expression. All primer 
sequences can be found from the original publications. 
4.8 RNA SEQUENCING  
RNA from the patient muscle samples were extracted as in 4.7 but further 
purified with the RNA purification kit (RNeasy; Qiagen). A total of one 
microgram of total RNA was used for the global transcriptomics analysis 
performed by the Beijing Genomic Institute (BGI). 50 base pair paired-end 
sequencing on Illumina sequencing platform was performed with approximate 
coverage of 26 million reads per sample. The reads were aligned against the 
GRCh38 Human genome assembly using STAR 2.5.0a. Read count was 
obtained with htseq-count, HTSeq 0.10.0, in union overlap resolution mode. 
Differential gene expression analysis was done with the Bioconductor DESeq2 
1.18.1 package. The fold changes in binary logarithmic scale and the respective 
p-values were extracted for pairwise comparisons. 
4.9 MITOCHONDRIAL DNA ANALYSES 
Total DNA was extracted using Phenol-chloroform-ethanol precipitation. 
Quantitative PCR (see 4.7) of DNA was used to analyze the copy number of 
mtDNA in relation to the genomic DNA. MtDNA deletion load was estimated 
with one-well triplex qPCR with 5’probed mtDNA primers ROX for D-loop, 
HEX for ND1 and FAM for ND4) (Rygiel, 2015). Visualization of the deleted 
mtDNA fractions was done with a long-PCR amplification protocol for 
mtDNA. All primer sequences can be found from the original publications. 
4.10 WESTERN BLOT 
Frozen tissues (10-20 mg) were homogenized in 50 mM Tris, 150 mM NaCl 
buffer with pH 7.6 with the Fast-Prep w-24 Lysing Matrix D (MP Biomedical) 
and Precellys w-24 (Bertin Technologies). Proteins were extracted with 1% 
Triton-X after homogenization. Proteins were run on SDS-PAGE and blotted 
on PVDF membranes (Trans-Blot Turbo transfer system, BioRad). Proteins 
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were visualized with antibodies listed in detail in the original publications after 
overnight incubation at +4°C. 
4.11 HISTOLOGY 
Immunohistochemistry, histochemistry, and immunofluorescence stainings 
were performed with formalin or paraformaldehyde fixed, paraffin embedded 
tissues. For immunological staining, antigen retrieval with heating in citric 
acid was performed and antibody staining performed according to standard 
protocols following instructions by the manufacturer. Details and list of 
antibodies used can be found in the original publications.  
Histochemical enzyme activity (COX/SDH) analysis and Oil-red-O staining 
for fat content were made from fresh frozen samples, embedded in Tissue-Tek 
O.C.T. mount, frozen in isopentane bath under in liquid nitrogen cooling. The 
staining procedures were performed according to (Ahola-Erkkila, 2010) and 
described in detail in the original publications. 
4.12 METABOLOMICS 
Targeted metabolomic analyses were performed from 20 mg of tissue material 
using Waters Acquity ultra performance liquid chromatography (UPLC) and 
triple-quadrupole mass spectrometry according to (Nandania, 2018).  
4.13 SERUM BIOMARKER MEASUREMENTS 
Measurement of serum biomarkers was performed with enzyme linked 
immunosorbent assays (ELISA) according to the manufacturer’s instructions. 
Standard human serum or plasma were stored in -80°C prior to analysis. The 
primary kit for patient samples was FGF21 ELISA from BioVendor, and the 
results were validated with FGF21 kit from R&D Systems. The GDF15 ELISA 
kit was provided by R&D Systems. Mouse serum was obtained from terminal 
heart puncture sample. The whole blood was let to clot for 15 minutes at room 
temperature, and then centrifuged for 3000x g for 15 minutes at +4°C. 
Quantikine Mouse Fgf21 immunoassay from R&D Systems was used for the 
measurements. Absorbance measurements were made with the SpectraMax 
190 absorbance microtiter plate reader. 
4.14 STATISTICAL ANALYSES 
Statistical analyses and graphical representation were performed with the 
GraphPad Prism v.6.0 or v.7.0 software.  
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Student’s t-test or ANOVA were used to compare experimental groups. In 
the biomarker study with patients, the normal cut-off values for serum 
concentrations were determined as the 95-percentile of healthy controls. 
Kruskal-Wallis test was used for multiple comparisons between the study 
groups.  
Outlier analysis was done using GraphPad’s ROUT method (Q=1%). 
Multiple testing correction for the metabolomics analyses was performed via 
the Benjamini-Hochberg method, using a corrected p-value below 0.2 as the 
threshold for significance.  
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5 RESULTS AND DISCUSSION 
5.1 MTDNA MAINTENANCE DEFECTS IN THE 
SKELETAL MUSCLE REMODEL ONE CARBON 
METABOLISM (III*) 
The genetic cause for mitochondrial myopathy of the patients studied in this 
thesis (publications I and III*) was either 1) a single primary sporadic mtDNA 
deletion or 2) mutations in the nuclear-encoded TWNK, leading to multiple 
mtDNA deletions. The latter is analogous to the Deletor mouse model. Both 
primary and secondary mtDNA deletions are associated with mitochondrial 
dysfunction and respiratory chain deficiency in the affected muscle tissues (see 
2.4.2 and 2.4.3 for details). 
5.1.1 INCREASED GLUCOSE UPTAKE IN DELETOR MUSCLE 
SUPPORTS SERINE DE NOVO SYNTHESIS 
To study the metabolic status of the affected muscle tissues, we performed 
targeted quantitative mass spectrometry-based analysis of ~100 metabolites 
in PEO patient and Deletor muscle samples. The human and mouse 
metabolomes showed a significant increase in the overall levels of amino acids, 
as reported before for the Deletor mouse (Ahola-Erkkila, 2010). In particular, 
levels of serine and glycine were highly induced in the muscle and heart of the 
Deletors. Expression of the serine synthesis enzymes phosphoglycerate 
dehydrogenase and phosphoserine phosphatase (Phgdh and Psat1) were 
reported to be induced in the Deletor muscle previously, when a robust 
induction of genes regulated by amino acid response element (AARE) was 
described in the mouse skeletal muscle (Tyynismaa, 2010) (2.5.1). Here we 
show that in the skeletal muscle and heart of Deletor mouse a high level of 
serine is accompanied with induced expression of the serine biosynthetic 
enzymes (Figure 8). 
PHGDH and PSAT1 divert 3-phosphoglyceric acid (3-PG), a three-carbon 
intermediate of glycolysis, towards de novo synthesis of serine. With a [U-13C]-
glucose (glucose m+6) flux assay we were able to show linear labeling of serine 
(serine m+3) during 5-25 minutes of uptake in the heart of the Deletor. 
Remarkably, incorporation of glucose carbons to serine in Deletor heart was 
significantly increased compared to control mice without changes in the 
labeled glycolysis end-products, pyruvate and lactate (Figure 8).  
To see whether increased serine biosynthesis influenced the total demand 
of glucose in the muscles, we did positron emission tomography (PET) using 
radiolabeled glucose analog, [18F]-FDG. In the [18F]-FDG PET, we detected a 
significant increase in glucose uptake to the Deletor muscle and heart over the 
25 minutes of recording (Figure 8).  
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Figure 8' Upper panel: Schematic presentation of glucose usage for serine biogenesis, red 
indicates induction in Deletor muscles (PSPH, phosphoserine phosphatase, was not 
measured). Steady state serine levels and mRNA expression of serine de novo 
synthesis enzymes PHGDH and PSAT1 in muscle tissues. Middle panel: Linear 
labeling of (m+3) serine from [U-13C]-glucose during the 25-minute uptake period 
in Deletor heart. Quantification of (m+3) lactate, (m+3) pyruvate and (m+3) serine 
in Deletor heart. Lower panel: [18F]-FDG biodistribution in a mouse, arrows point 
to skeletal muscle and heart, quantified on right. Statistical significance: *=p<0.05, 
**=p<0.01, ***=p<0.001. ****=p<0.0001. Abbreviations: 3-PG=3-Phosphoglyceric 
acid, 3-PHP=3-phosphohydroxypyruvate.  
In summary, these results of the steady state and flux metabolomics  
together with [18F]-FDG PET suggest that the excess glucose in mitochondrial 
myopathy muscle was not directed to glycolysis for compensation of 
mitochondrial respiratory chain deficiency but was used to synthesize serine. 
This finding revealed a previously uncharacterized metabolic adaptation of the 
post mitotic muscle in mitochondrial disease. 
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5.1.2 SERINE IS SHUTTLED TO DRIVE TRANSSULFURATION IN 
DELETOR MUSCLE 
Analysis of evolutionary conservation can reveal pathways that show 
functional interdependence with each other. As PHGDH has been reported to 
be the determinant of 3-PG fate towards serine also in cancer cells (Locasale, 
2011) (Figure 8), we utilized a co-evolution analysis tool CLIME (clustering by 
inferred models of evolution, http://gene-clime.org) (Li, 2014) to predict 
pathways dependent on PHGDH driven serine synthesis. The analysis strongly 
suggested co-evolution with the transsulfuration enzymes cystathionine 
gamma lyase (CTH) and cystathionine beta synthase (CBS). In a western blot, 
CBS was not detectable in muscle and heart tissues but CTH and another 
transsulfuration enzyme, glutamate-cysteine ligase (GCL), showed increased 
expression (Figure 9).  
In transsulfuration, cysteine and glutathione are produced from 
homocysteine, serine, glutamate and glycine. In the [U-13C]-glucose flux assay 
of Deletor heart, we detected efficient and rapid labeling of (m+5) glutathione, 
indicating incorporation of glucose carbons through serine and glycine (Figure 
9). In the steady-state targeted metabolomic analysis, transsulfuration 
intermediates cystathionine and gamma-glutamylcysteine were increased, 
supporting the drive for glutathione synthesis (Figure 9).  
Glutathione exists in a dynamic balance of oxidized and reduced forms in 
a cell. Major consumers of reduced glutathione are the ROS-scavenging 
enzyme glutathione peroxidase and glutathione reductase which supports 
reductive biosynthetic reactions. In Deletor heart we detected increased 
glutathione reductase and normal glutathione peroxidase activities (Figure 9), 
implying that the increased production of glutathione is utilized in synthetic 
reactions rather than counteracting oxidative stress, often linked to 
mitochondrial respiratory chain deficiency (Kirkinezos, 2001; Atkuri, 2009). 
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Figure 9' Left: Glutathione synthesis and reactions in Deletor muscle and heart. Flux of 
glucose carbons (red circles) throughout glutathione synthesis pathway in Deletor 
muscle and heart. Red text indicates increased metabolites in the steady state 
targeted metabolomics, Western blot or qPCR. Right, top: Western blot of 
transsulfuration enzymes in Deletor skeletal muscle and heart. Right, bottom: 
Enzyme activities of major enzymes that utilize reduced glutathione, glutathione 
reductase and glutathione peroxidase. Statistical significance: *=p<0.05. 
De novo deoxy nucleotide (dNTP) synthesis by ribonucleotide reductase is 
one of the many reactions dependent on reduced glutathione availability 
(Sengupta, 2014). In the muscle of Deletor, we indeed found increased and 
imbalanced dNTP pools, possibly reflecting the serine driven boosting of 
glutathione synthesis. A similar response was also reported in a mammalian 
cell culture model with acute mtDNA depletion (Bao, 2016). Intriguingly, 
serine biosynthesis has been shown to be essential for growth and survival of 
multiple cancer cell lines, ultimately through support of active nucleotide 
production for rapid proliferation (Locasale, 2011; Possemato, 2011; Locasale, 
2013; Labuschagne, 2014; Mehrmohamadi, 2014; Pacold, 2016). Together, 
our findings suggest induction of nucleotide metabolism in a post-mitotic 
tissue with mtDNA replication defects, mimicking the metabolic adaptations 
of proliferative cancer cells. 
In post-mitotic tissues, the main user of dNTPs is the mtDNA and impaired 
nucleotide pool regulation is a major cause of mitochondrial deletion and 
depletion syndromes (Suomalainen, 2018). Moreover, excess nucleotides in an 
already imbalanced nucleotide pool environment have been shown to be 
genotoxic in mice deficient of pyrimidine nucleotide conversion (Garcia-Diaz, 
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2014). In Deletor, we did not detect increased point mutation load, at least in 
the mtDNA. Therefore, it remains to be studied whether boosting of dNTP 
pools plays a protective or disruptive role in pathophysiology of primary 
mtDNA deletion diseases.  
?5-5;' 6*$!"(4,&'2,)7*%:%,)$'(2'6,$(&3().%,!4'69(:!$39'
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One-carbon metabolism refers to reactions that transfer single carbon units 
(1C) in the form of methyl groups (CH3) for biosynthetic reactions such as 
purine and dTMP syntheses, formyl modification of mitochondrial tRNAMet, 
DNA and histone methylation, lipid head group modifications and creatine 
metabolism. Methyl cycle and folate cycle are essential players in maintenance 
of the methylation capacity in a cell. See schematic representation of 1C 
metabolism in Figure 10. (Ducker, 2017). 
 
Figure 10' Simplified scheme of folate and methyl cycle interconnection and dependent 
cellular pathways. Red arrows and balls highlight our findings of glucose-driven 
induction in 1C metabolism and transsulfuration in mitochondrial myopathy 
muscle.  
Serine is not only needed as precursor for transsulfuration reactions, as 
shown in Figure 9, but also serves as a major carbon donor for cellular 1C 
reactions through the folate cycle (Figure 10). In the folate cycle, folate, or 
vitamin B9, is first transformed to tetrahydrofolate (THF). THF accepts a 1C 
unit in different oxidation states and is cycled in a sequence of reactions 
compartmentalized in the mitochondria and cytoplasm. By transcriptome 
analysis, we have previously reported induction of mitochondrial folate cycle 
enzyme, methylenetetrahydrofolate dehydrogenase (MTHFD2), in the muscle 
of the Deletor mice (Tyynismaa, 2010). Encouraged by this, we measured 
folate cycle intermediates (forms of THF) and detected increased levels of 
5,10-methenyl-THF and 5-methyl-THF together with high protein expression 
of mitochondrial enzymes MTHFD2 and MTHFD1L, suggesting major 
alterations in mitochondrial and cytoplasmic folate cycle.  
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In different cell types, or upon nutritional stress, the direction of THF-
cycling reactions can be reversed to favor the availability of 1C units between 
the different synthetic pathways (Ducker, 2016, 2017). In Deletor muscle, we 
observed an increased amount of purine metabolism intermediates that 
together with dNTPs and transsulfuration could indicate increased need of 
nucleotides for mtDNA replication stress (5.1.2). 
The mitochondrial folate cycle and mitochondrial translation are directly 
linked through formylation of the mitochondrial initiator methionine, formyl-
methionine (fMet and fMet-tRNAMet). Mutations in mitochondrial methionyl-
tRNA formyltransferase (MTFMT) that generates the fMet-tRNAMet 
compromise mitochondrial protein synthesis leading to OXPHOS deficiency 
(Tucker, 2011). In Deletors, mitochondrial translation assay has indicated 
modestly decreased organellar translation (unpublished data of ASW 
laboratory). In Deletor muscle, however, the large mtDNA deletions directly 
impair  several tRNAs and affect their levels, possibly directly reducing the rate 
of translation in mitochondria. We do, however, detect multiple changes 
especially in the mitochondrial part of the folate cycle that could potentially 
lead to currently uncharacterized blocks or imbalances in formulation 
reactions, and therefore further impair the initiation of mito-translation.  
Folate and methyl cycles are interdependent, linked by a folate cycle 
intermediate, 5-methyl-THF. In the Deletor muscle, we detected high level of 
5-methyl-THF, as well as betaine, choline and threonine that can also be 
utilized to maintain methyl cycle (Barlowe, 1988; Christensen, 2006; Tibbetts, 
2010; Ducker, 2017) (Figure 10). As shown in the previous chapters of section 
5.1, our results suggested that the usage of folate cycle could be partially 
boosted to support methyl cycle to drive transsulfuration (Figures 9 and 10). 
However, methylation of homocysteine to re-generate methionine in methyl 
cycle is essential to maintain proper ratios of S-adenosyl methionine (SAM) 
and de-methylated S-adenosyl homocysteine (SAH). SAM is the major 1C 
donor utilized by methyltransferase enzymes, for example in synthesis of 
creatine, in epigenetic modification of nucleic acids and histones, and 
synthesis of membrane phospholipids, such as phosphatidylcholine. Increased 
SAH/SAM ratio is an indicator of methyl donor deficiency, and is observed in 
folate deficiency and defects in other vitamins essential for folate and methyl 
cycles (Walker, 2017). In Deletor muscle, however, SAH and SAM levels were 
normal and a qualitative assay of bulk DNA methylation did not show 
difference from healthy controls. Nevertheless, further studies on the cellular 
trans-methylation reactions are with high relevance for mitochondrial disease 
pathology, as increasing evidence have already shown the importance of 
methylation balance in robust epigenetic gene expression regulation and 
pathophysiology of neurological disorders (Gao, 2018; Zhang, 2018).   
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5.2 MITOCHONDRIAL INTEGRATED STRESS 
RESPONSE (ISRMT) IS CONSERVED AND 
SEQUENTIAL IN MAMMALS (I) 
 
For comprehensive and unbiased characterization of the transcriptome in 
humans, we performed RNA-sequencing of AdPEO muscle samples. In 
patients with mtDNA deletions, we detected robust induction of the genes 
important for the metabolic reprogramming described in 5.1 (III*). More 
specifically, transcripts of the mitochondrial folate pathway (MTHFD1 and 
MTHFD2) and serine metabolism (PHGDH, PSAT1 and Serine 
hydroxymethyltransferase, SHMT2) were significantly increased. Also, the key 
secretory hormone-like cytokines, FGF21 and GDF15, were among the most 
significantly upregulated transcripts, replicating the transcriptional 
characteristics of initial AARE-response described in Deletors (Tyynismaa, 
2010) (see 2.5.1). The transcriptional AARE and the metabolic stress 
responses to mitochondrial insults in mammalian muscle are hereafter 
collectively termed the mitochondrial integrated stress response, or ISRmt. 
Our previous studies describing the ISRmt in mitochondrial myopathy 
(patients and Deletor) were mainly cross-sectional, performed in the advanced 
stage of pathogenesis. However, expression of Fgf21, a key AARE-driven gene, 
was shown to increase along with the progression of histological respiratory 
chain deficiency in muscle fibers (Tyynismaa, 2010). Therefore, we intended 
to study whether we can dissociate different phases for the ISRmt and identify 
the driving transcription factors.  
For the dynamic characterization of ISRmt, we systematically collected 
Deletor tissues prior to (9 months of age) and throughout the manifesting 
period (12-24 months of age), and analyzed gene expression of key 
ISRmt/AARE factors. In the early phase of pathology, corresponding with 
appearance of the first detectable COX-negative fibers at 12 months of age, we 
detected transcriptional induction of Fgf21, Gdf15 and Mthfd2. The first stage 
therefore marked initiation of systemic signaling with hormones, together 
with mitochondrial one-carbon metabolism. Induction of the serine 
biosynthetic enzymes, Phgdh and Psat1, was apparent only months later, 
around 18-20 months of age, after the appearance of SDH-positive fibers and 
activation of mTORC1 (Figure 11). The clear temporal difference between 
initiation of serine synthesis and the first stage AARE-genes suggests that the 
glucose/serine-driven metabolic rewiring is not the primary response to 
mitochondrial dysfunction in muscle, but could be initiated in response to, or 
regulated by, the first stage ISRmt. 
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Figure 11 Schematic representation of the ISRmt phases and UPRmt relative to signs of disease 
progression in muscle of Deletor. 
Mitochondrial unfolded protein response (UPRmt) has strongly featured in 
the discussion of mitochondrial stress signaling for the last decade. The UPRmt 
includes expression of numerous heat shock proteins (HSP), chaperones and 
proteases with undisputed mechanistic importance in mitochondrial stress 
signaling in C. elegans models of mitochondrial dysfunction (Haynes, 2007; 
Durieux, 2011; Nargund, 2012; Merkwirth, 2016; Zhang, 2018). In mammals, 
evidence for UPRmt/HSP induction in mitochondrial pathology derives from 
cultured cells with proteotoxic stress (Zhao, 2002) or severe mitochondrial 
dysfunction due to knockout of essential proteins in a tissue-specific context 
(Pulliam, 2014; Seiferling, 2016). In Deletor mouse muscle, we found only a 
modest increase in gene expression of heat shock protein 70 (Hsp70), and 
increased mitochondrial localization of HSP10, HSP60 and LONP1 proteins, 
but only at the very late stage of the mouse lifespan, after 22 months of age 
(Figure 11). Similarly, in RNA sequencing data of AdPEO patients’ muscle, we 
did not detect induction of UPRmt/HSP markers. This data suggested that the 
UPRmt, as described in the worm or knockout models, is not significant in 
muscle manifesting mtDNA expression disorders of mammals. This suggests 
that the underlying molecular and biochemical events are profoundly different 
in different model systems and cells, causing the tissues to respond with a 
different combinations of stress markers.  
In a C. elegans model of neuronal respiratory chain deficiency, the 
activated stress responses were described to spread from the affected tissue to 
distant, healthy cells through secreted molecules or ‘mitokines’ (Durieux, 
2011) (see 2.5.1). In Deletor model, mtDNA deletions and respiratory chain 
deficiency is detected in muscle and neural tissues (and brown adipose tissue) 
(Suomalainen, 1992; Tyynismaa, 2005; Khan, 2014), although the mutant 
Twinkle is ubiquitously expressed. To study whether the secreted ISRmt 
components FGF21 and GDF15 (or unknown other factors) could  initiate 
stress responses in the ‘non-affected’ secondary tissues, similar to the worm, 
we screened gene expression of Fgf21, Mthfd2, Hsp60 and Hsp70 in skeletal 
muscle, heart, liver, adipose tissues, lungs and kidneys. Importantly, we only 
detected expression of Fgf21 and Mthfd2 in the primarily affected skeletal 
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muscle and heart, as well as marginal induction of Mthfd2 in brown adipose 
tissue, and not in the brain or peripheral tissues. This indicated that the 
mitochondrial stress responses, caused by mitochondrial replicative stress and 
mtDNA deletions, do not get induced in secondary tissues without the primary 
mitochondrial defect. 
5.2.1 ISRMT: MIX-AND-MATCH OF DIFFERENT ATFS 
AARE-promoters are bound by activating transcription factors (ATFs) that 
drive expression of downstream genes. ATF4 and ATF5 have been 
predominantly studied in the context of mammalian mitochondrial insults in 
cell culture conditions (Fiorese, 2016, Quirós, 2017). In a cell culture model of 
mtDNA depletion, ATF4 was described to drive activation of ISRmt (Bao, 
2016). Patient derived cell lines do not, however, usually preserve multiple 
mtDNA deletions in culture conditions. Therefore, to study dynamics of ISRmt 
and ATFs in culture we challenged mtDNA expression with reversible 
chemical inhibition of mitochondrial translation by actinonin. Actinonin is 
previously known also to induce expression of AARE-genes  in culture 
(Richter, 2013) and is therefore mechanistically close to translation defect in 
a system with mtDNA deletions (e.g. the Deletor). In actinonin treated 
fibroblasts (mouse and human) and mouse myoblasts we showed that the 
components of the mammalian ISRmt (Figure 11) were robustly induced 
following the gradual inhibition of mitochondrial translation. Out of ATFs 1-7, 
only ATF3, 4 and 5 were robustly induced in transcriptional assays. RNA-
interference experiments showed that out of ATFs 3-5 only ATF4 was needed 
for ISRmt activation in vitro.  
To compare weather the established ATFs 3-5 of ISRmt in vivo were similar 
to culture conditions, we analyzed expression data of Deletor mouse and 
AdPEO patient muscle. Different to cultured cells on actinonin or mtDNA 
depletion model (Bao, 2016), we found ATF5 to be robustly expressed together 
with the ISRmt factors. We did not detect increased expression of ATF3 and 
ATF4 in patients, but saw their modest induction in late stage of disease 
progression in Deletor muscle, along with UPRmt.  
In summary, we suggest that ATF5 is the primary ATF associated with 
ISRmt in post-mitotic mitochondrial myopathy muscle in vivo, different from 
proliferating cells in culture. Our work highlights that that ATFs work in 
concert, depending on the type of stress, cell type or organism, and that there 
likely is no definite uniform driver for the stress responses in mitochondrial 
disease. 
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5.3 FGF21 DRIVES THE DYNAMICS OF LOCAL AND 
SYSTEMIC PATHOPHYSIOLOGY (I) 
FGF21 was one of the first components of ISRmt to get induced in the sequence 
of pathology of Deletor muscle, as presented above. Importantly, FGF21 is an 
endocrine hormone with potential to tune the metabolism of the whole body 
upon chronic exposure. Therefore, we studied the local and systemic effects of 
chronic FGF21 signaling upon mitochondrial myopathy, and genetically 
inactivated FGF21 in the Deletor mouse.  
5.3.1 GENERATION, VALIDATION AND LIMITATIONS OF THE 
DELETOR-FGF21 KNOCKOUT MODEL 
“Essentially, all models are wrong, but some are useful.”  
–George E. Box 
The Deletor-FGF21KO mouse (DEL-FKO) was generated by sequential 
crossing of Fgf21LoxP/LoxP mice (Potthoff, 2009), ubiquitously Cre-expressing 
mice [PGK-Cre, (Lallemand, 1998)] and Deletors (Tyynismaa, 2005). A full-
body knockout of FGF21 was confirmed by lack of gene and transcript from 
multiple tissues, and by fasting serum FGF21 measurements. All mouse 
strains had normal lifespan and appearance.  
Lack of FGF21 in essential metabolic organs, such as liver and adipose 
tissues, have been reported to compromise the systemic responses to 
nutrition, carbohydrate and fat metabolism (Badman, 2007, 2009; Potthoff, 
2009; Xu, 2009). Therefore, the ubiquitous FGF21KO background always 
must be considered, especially in interpretation of the cell non-autonomous 
traits. Direct comparison of Deletors and DEL-FKO in metabolic assays need 
to be normalized to wild type or FKO background.  
Second, the experimental setup using ubiquitous FGF21KO does not allow 
FGF21-related effects to be specifically attributable to the muscle derived 
FGF21. Unfortunately, a muscle-specific knockout we initially made (with 
ACTA1 driven Cre-recombinase, unpublished), had a significant leak of FGF21 
expression from the key tissues of interest, the skeletal muscle and heart, and 
was therefore not suitable for this study. On the other hand, a full body 
knockout conveniently eliminates compensatory or interfering expression of 
FGF21 from secondary and subtly affected tissues, such as the brown adipose.  
In summary, the limitations of our model disable studies on the tissue-to-
tissue interactions dynamically or with mechanistic certainty. Therefore, we 
do not propose receptor interactions or exact molecular mechanisms for the 
FGF21-effects in the target tissues. However, as we have demonstrated that 
skeletal muscle and heart are the primary significant sources of FGF21 in the 
Deletor (5.2), a ubiquitous knockout of FGF21 essentially models the muscle-
specific knockout set-up in laboratory animals with minimal need to initiate 
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physiological fasting responses and metabolic adaptation in standard 
maintenance conditions. Ultimately, we state that results obtained from the 
DEL-KO, in comparison to Deletors and healthy controls, can confidently state 
the dependence or independence of the phenotypic features on FGF21 in the 
context of mitochondrial disease. 
5.3.2 FGF21 PREDICTABLY CAUSES BROWNING OF WHITE 
ADIPOSE TISSUE AND BODY WEIGHT LOSS IN DELETOR 
Circulating FGF21 has been reported to promote leanness, low adiposity and 
increased energy expenditure in mouse models (2.5.2). Fitting to this, Deletors 
at the age of disease manifestation are lean, have reduced liver fat and are 
resistant to diet-induced obesity (Ahola-Erkkila, 2010; Tyynismaa, 2010). The 
lean phenotype has been rightfully hypothesized to be mediated by muscle 
derived FGF21, as was described for autophagy deficient Atg7muscle-/- mice with 
robust FGF21 response and subsequent loss of adipose tissue (Kim, 2013).  
In Deletors of 16-20 months of age, high serum FGF21 is detected and body 
mass starts to progressively decline (Figure 12). DEL-FKO mice, on the other 
hand, show normal body weight progression almost throughout their lives. 
Systemic white adipose tissue browning is a known consequence of chronic 
FGF21 exposure, and is shown also in mice with mitochondrial uncoupling in 
muscle (Keipert, 2014). Here, we show that the small adipose volume of 
Deletors is associated with FGF21 mediated browning, as the white adipose 
tissue of DEL-FKO mice appeared similar to wild type controls (Figure 12). 
Loss of liver fat was not completely restored by FGF21 knockout (Figure 12). 
This could be explained by a so far uncharacterized primary pathogenesis in 
the liver tissue by Twinkle mutation, or by redundant regulation of fat 
metabolism by unknown factors, or by metabolic hormone and mitochondrial 
disease biomarker GDF15 (Yatsuga, 2015; Chung, 2017).  
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Figure 12' Top: Increase of serum FGF21 (S-FGF21) in ageing Deletors and body weight 
progression, presented as percentage from 11 months of age. Stars indicate 
significant difference of experimental group and WT. Bottom: Fat droplet size 
(hematoxylin-eosin staining) on subcutaneous white adipose tissue (WATsc) and 
brown/beige adipocytes indicated with uncoupling protein 1 (UCP1) 
immunohistochemistry. Liver stained with Oil-red-O for lipids. Statistical 
significance: *=p<0.05, **=p<0.01, ***=p<0.001. ****=p<0.0001. 
GDF15 was found to be robustly induced in a mouse model of respiratory 
chain ablation and UPRmt induction due to knockout of an accessory subunit 
of the mitochondrial ribosome (CRIF1) in skeletal muscle (Chung, 2017). 
FGF21 was also induced, but unlike GDF15, presented no correlation with 
mitochondrial stress factors in expression analysis of CRIF1KOmuscle. In the 
CRIF1KOmuscle model, GDF15 caused cell-non-autonomous improvement of 
energy expenditure, insulin sensitivity, oxidative metabolism and lipolysis in 
liver and adipose tissues (Chung, 2017), similar to the effects of FGF21 in 
Deletor. Interestingly, the underlying insults to the mitochondrial respiratory 
chain are profoundly different in Deletor and CRIF1KOmuscle models: Deletor 
manifests mtDNA deletions and respiratory chain deficiency in the form of low 
Adiposity in tissues
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activity of COX and ragged red fibers, whereas CRIF1KOmuscle mice have 
marked depletion of respiratory chain complexes (Chung, 2017), possibly due 
to impaired insertion into inner membrane (Kim, 2012). These examples by us 
and others highlight the complexity of local stress responses (covered in 
chapter 5.2) that originate from mechanistically different primary insults, a 
concept discussed further for FGF21 and GDF15 in chapters 5.7 and 5.8. 
5.3.3 FGF21 HAS NO EFFECT ON THE PRIMARY DISEASE SIGNS OF 
MITOCHONDRIAL MYOPATHY 
To evaluate the effects of FGF21 on local disease progression in muscle, we 
first assessed the primary pathological hallmarks: mtDNA deletions, 
respiratory chain deficient muscle fibers and respiratory chain complexes. At 
24 months of age, none of these disease signs were significantly changed in 
DEL-FKO relative to Deletors. We also assessed gene expression of 
representative ISRmt/AARE genes (Gdf15, Mthfd2, Trib3 and Asns) that 
previously showed temporal co-expression with FGF21. Similar to 
mitochondrial pathology, these factors showed induction independently of 
FGF21. We also found that out of the ISRmt-relevant ATFs 3-5 (5.2.1), ATF5 
expression was upregulated regardless of presence or absence of FGF21, 
whereas expression of ATF3 and ATF4 was moderately up in Deletors but did 
not show any induction in DEL-FKO. These results demonstrate that FGF21 
does not contribute to the early disease pathogenesis, demonstrates fixed 
regulation and no interdependence inside the first-stage ISRmt, and further 
support the hypothesis of ATF5 as the mammalian driver of mitochondrial 
stress in muscle (5.2.1).  
5.3.4 FGF21 IS ESSENTIAL FOR TRANSSULFURATION AND ONE-
CARBON METABOLISM IN MITOCHONDRIAL MYOPATHY 
In the pathophysiology of mitochondrial myopathy muscle, glucose uptake, 
serine de novo synthesis and induction of transsulfuration marked the 
metabolic rearrangements in Deletor muscle (Figures 8 and 9). In the 
sequence of transcriptional response, FGF21 expression preceded induction of 
serine biosynthetic enzymes, PHGDH and PSAT1 (Figure 11). We therefore 
measured expression of serine synthesis enzymes and protein amount of 
transsulfuration enzyme CTH in DEL-FKO. Remarkably, in DEL-FKO at 24 
months of age, we did not observe induction of Phgdh, Psat1 or CTH, markedly 
elevated in Deletors. Importantly, uptake of [18F]-FDG was not induced in the 
affected muscle and heart tissues of DEL-FKO (see biodistribution of [18F]-
FDG in Figure 14). Furthermore, we noted that in muscle of DEL-FKO mice, 
levels of the methyl donors 5-methyl-THF, betaine and choline, and trans-
methylation intermediates guanidinoacetic acid and creatine were normal, 
whereas in Deletor they are induced compared to healthy controls.  
Results and discussion 
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Together, the metabolomics and expression data suggest that persistent 
induction of FGF21 upon mitochondrial dysfunction is required for the robust 
one-carbon metabolism rearrangements in mitochondrial myopathy, 
especially for the glucose driven serine synthesis and transsulfuration 
induction. Scheme in Figure 13 summarizes these key changes around methyl 
cycle and transsulfuration pathways in muscle of Deletors and DEL-FKO. 
Figure 13' Schematic presentation of the key transsulfuration and methyl cycle reactions with  
summary of the findings in skeletal muscle of Deletor and DEL-FKO. Color codes: 
Red=induced, Black=normal, Grey=not measured/not detected. Abbreviations: 
CBS=Cystathionine beta-synthase, CTH=Cystathionine gamma-lyase, 
GCL=Glutamate-cysteine ligase, GS=Glutathione synthetase, Hcy=homocysteine, 
Phgdh=Phosphoglycerate dehydrogenase, Psat1=Phosphoserine aminotransferase, 
SAH=S-adenosyl homocysteine, SAM=S-adenosyl methionine, 
THF=tetrahydrofolate.  
?5;5?' #9#$*6,&'74/&(#*':%*2*%*)&*#',)'6,$(&3().%,!4'
69(:!$39'!%*'6(./4!$*.'"9'2720-'
To obtain more insight into role of FGF21 in systemic nutrient metabolism, we 
performed in vivo biodistribution assays of radio-labelled glucose and fatty 
acid analogues, [18F]-FDG and [18F]-FTHA, respectively. First, in Deletors, the 
affected muscle and heart, as well as white adipose tissue with browning 
phenotype, showed significantly increased [18F]-FDG uptake. Moreover, 
several other tissues of the Deletor showed changes in glucose uptake. We 
observed a decrease in relative [18F]-FDG uptake in brain, liver, pancreas and 
spleen, and less [18F]-FDG was retained in serum of Deletors after the uptake 
period, possibly reflecting the increased demand of the muscle tissues. 
Interestingly, DEL-FKO mice had [18F]-FDG uptake comparable to FKO 
controls (p>0.05) in all the tissues we measured (Figure 14). These results 
show that 1) FGF21 drives glucose uptake especially in the affected muscle and 
heart, 2) browning of white adipose tissue is reflected as an increased 
metabolic activity, and 3) the systemic exposure to FGF21 potentially 
modulates glucose preferences of the brain and whole periphery.  
On the other hand, uptake of the palmitic acid analog, [18F]-FTHA, was not 
changed in comparison of Deletor and wild type nor in DEL-FKO and FKO. 
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Given the well-known actions of FGF21 in boosting of fatty acid metabolism in 
rodents, it was somewhat surprising that the uptake of fatty acids ([18F]-
FTHA) was not changed in the tissues of Deletor (or DEL-FKO).  
In summary, these results suggest that the interplay of mitochondrial 
myopathy and FGF21 mainly affects glucose but not long chain fatty acid 
uptake in the primarily affected or the secondary tissues (Figure 14).  
 
Figure 14' In vivo glucose (upper panel) and fatty acid (lower panel) uptake assays with [18F]-
labeled analogs. Deletors and DEL-FKO mice are superimposed with the 
appropriate healthy controls, wild type and FKO, respectively. Ln2 of fold change 
for SUV (Standard uptake value) presented, statistical significance: *=p<0.05, 
**=p<0.01, ***=p<0.001. 
?5;5C' 2!$$9'!&,.'(<,.!$,()'!).'2720-',)'6,$(&3().%,!4'
69(:!$39'K,'!).',,,LM'
In metabolic characterization of patient muscle and serum, we demonstrated 
profound increase in amino-acid and acyl-carnitine pools, and the profile was 
similar in the Deletor muscle (III*). Interestingly, in publication I, we showed 
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that in DEL-FKO muscle, levels of long-chain acyl-carnitines were still 
elevated, suggesting that FGF21 was not the reason for accumulation in the 
affected muscles.  
Acyl-carnitines are fatty acid molecules attached to a carnitine carrier, 
committed for beta-oxidation in mitochondria (see 2.1.2), and also utilized as 
markers of fatty acid oxidation disorders (Sim, 2002). Accumulation of acyl-
carnitines in muscle of AdPEO and Deletor therefore suggest altered 
utilization, or partially blocked beta-oxidation in the muscles with 
mitochondrial dysfunction. Indeed, impaired fatty acid oxidation is a well-
known secondary manifestation of respiratory chain deficiency. 
Mechanistically the disturbance can link to disbalanced NAD+/NADH pools 
(see 2.1.2), and indirect evidence suggests that deficient mitochondrial beta-
oxidation can disturb mitochondrial membrane potential and therefore 
critically impair assembly and function of the mitochondrial respiratory chain 
(Lim, 2018). These interesting questions on causative relations OXPHOS and 
beta-oxidation in mtDNA instability are not mechanistically answered by our 
studies, but suggest involvement of fatty acid metabolism in the primary 
pathophysiology and stress signaling, see discussion below. 
Previous study from our group and two examples from the fatty acid 
oxidation field suggest shared stress responses. We have shown that in the 
respiratory chain deficient fibers of Deletor mTORC1 is activated and drives 
the expression of FGF21/AARE and the one-carbon metabolism changes 
(Khan, 2017). Interestingly, in two models of muscle or heart specific fatty acid 
oxidation deficiency, an essentially identical induction of metabolic stress 
signaling is described. A Cpt1bMuslce-/- mouse with inhibition of acyl-carnitine 
transport over mitochondrial membrane (Vandanmagsar, 2016) and a 
AcslHeart-/- mouse with impaired cytoplasmic conversion of long-chain fatty 
acids to acyl-CoAs (Schisler, 2015) both activate mTORC1 and present a 
profound increase in expression of FGF21. The response in the AcslHeart-/- 
model impressively demonstrates determinative expression of several AARE-
genes: Fgf21, Gdf15, Mthfd2, Trib3 and Asns. Moreover, the AcslHeart-/- even 
presents increased drive towards cysteine and glutathione synthesis through 
transsulfuration. These examples spark an interesting hypothesis for beta-
oxidation as potential scanning point for mitochondrial (dys)function and 
induction of the ISRmt. Therefore, the initial signal for FGF21/AARE response 
might originate from the primary or secondary impairment of beta oxidation 
and energy metabolism, upon which induction of FGF21 seems physiologically 
relevant.  
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FGF21 is a known regulator of metabolism, acting on the interplay between 
the periphery and hypothalamus (2.5.2 and 2.5.3). Based on the literature and  
widely altered biodistribution of [18F]-FDG in Deletors (Figure 14), we 
hypothesized that chronically high FGF21 in the circulation could influence 
the brain.  
?5=5-' 2720-'.%,+*#'74/&(#*'/:$!A*',)'$3*'&!0''
Parallel to the in vivo biodistribution studies (Figure 14), we performed 
autoradiography of brain sections after [18F]-FDG uptake. From the series of 
coronal sections, we identified an intense and specific [18F]-FDG signal, 
located in the dorsal hippocampus (DHC) of Deletors. We quantified the [18F]-
FDG signal of multiple brain regions, including the dorsal and ventral 
hippocampus, hypothalamus, cortex and striatum, and only found change in 
the Deletor DHC. Strikingly, FGF21 was required for the intense glucose 
uptake to the DHC of Deletors, as [18F]-FDG signal in the DHC of DEL-FKO 
brain was similar to healthy controls (Figure 15). 
 
Figure 15' Digital autoradiography of coronal brain sections in DHC and quantitation of [18F]-
FDG intensity in different brain regions (PSL=photostimulated luminescence). 
Statistical significance: ****=p<0.0001. Abbreviations: DHC=Dorsal hippocampus, 
VHC=ventral hippocampus, HT=hypothalamus, CTX=cortex (visual), 
CPu=caudoputamen of striatum.  
?5=50' 2720-G.*:*).*)$'6!),2*#$!$,()'(2'6,$(&3.)%,!4'
:!$3(4(79',)'$3*'&!0''
Previously, Deletors were known to harbor distinct COX-/SDH+ cell 
populations in purkinje cell layer of cerebellum and hippocampus (Tyynismaa, 
2005). Guided by the increased glucose uptake, we now focused on the Deletor 
DHC and demonstrated a depletion of Complex IV (MT-CO1) and 
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mitochondrial proliferation (SDHA and TOM20), classical signs of respiratory 
chain deficiency in muscle. Intriguingly, mitochondrial respiratory chain 
deficiency in Deletors was strictly localized to the CA2 sub-region of the 
hippocampus, and completely absent in the neighboring hippocampal regions 
CA1, CA3 and dentate gyrus, as well as extra-hippocampal regions such as the 
cortex and hypothalamus. Most importantly, FGF21 was indispensable for 
MT-CO1 depletion and mitochondrial proliferation in the CA2, as DEL-FKO 
mice were indistinguishable from the healthy controls (Figure 16), as was the 
[18F]-FDG uptake presented before (Figure 15).  
 
Figure 16' Top: Schematic presentation of mouse brain in sagittal orientation with a detailed 
map of hippocampus divided to major sub-regions and layers. Bottom: 
Immunodetection of mitochondrial respiratory chain Complex IV (MT-CO1, mtDNA 
encoded), Complex II (SDHA, nuclear encoded) and mitochondrial outer membrane 
protein (TOM20). Visuals: boxes indicate the sp-layer of CA2 in MT-CO1 staining, 
arrows point to SDHA and TOM20 positive neuronal projections of sr-layer. 
Abbreviations: DG=dentate gyrus, so=stratum oriens, sp=stratum pyramidale, 
sr=stratum radiatum, slm=stratum lacunosum-moleculare. 
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In Deletors, mtDNA deletions underlie the respiratory chain dysfunction in 
the muscle, heart and brown adipose tissue (Tyynismaa, 2005; Khan, 2014, 
III*). The DHC (containing most of the anatomical CA2), VHC and cerebellum 
showed equal amounts of mtDNA deletions in Deletors and DEL-FKO, similar 
to the skeletal muscle. This indicates that the metabolic pathology (glucose 
uptake and respiratory chain deficiency) in CA2 did not affect the primary 
mtDNA mutagenesis in Deletor background.  
To study whether FGF21 alone influenced glucose metabolism of the 
different brain areas, we analyzed [18F]-FDG uptake in wild type mice that 
were either injected with recombinant mouse FGF21 or fasted for 24 hours to 
induce the physiological starvation response with hepatic expression of 
FGF21. As a result, [18F]-FDG uptake was increased in the whole brain of 
fasted mice, but hippocampus, hypothalamus or cerebellum were not affected 
by fasting or recombinant FGF21.  
These results indicate that FGF21-dependent mechanisms modify the 
glucose metabolism and mitochondrial pathology specifically in the CA2 of 
hippocampus expressly in the context of primary mitochondrial dysfunction 
(mtDNA deletions).  
5.4.3 FGF21 LINKS THE CA2 TO NON-HOMEOSTATIC METABOLIC 
REGULATION? 
The Ammon’s horn of hippocampus consists of CA1, CA2, C3 and dentate 
gyrus. Of the CA-regions, CA2 was the last to be identified and its role is only 
recently being elucidated in the canonical hippocampal circuits; spatial 
processing, social behavior and temporal encoding (Dudek, 2016; Tzakis, 
2019). Structurally, CA2 differs from the neighboring CA-regions significantly. 
Even on a simple histology, CA2 structure is defined by presence of large and 
loosely packed pyramidal neurons, different from the neighboring CA1/CA3. 
Expression of specific markers, such as purkinje cell protein 4 (PCP4) and 
regulator of G protein signaling (RGS14), indisputably identify CA2 (Dudek, 
2016; Gerber, 2019). 
CA2 has attracted great interest in neurobiology as it has shown to present 
superior resistance to damage by injury (Dudek, 2016). Calcium ion buffering 
capacity and extrusion rates are nearly four times greater compared to 
neighboring CA1, and for example a robust calcium transporter of inner 
mitochondrial membrane ryanodine receptor 1 (Ryr1) is highly expressed in 
CA2 (Jakob, 2014). Mitochondria are central in cellular calcium metabolism, 
and along with enrichment of calcium factors, mitochondrial transcripts are 
generally overrepresented in transcriptome of CA2 (Farris, 2019). 
Furthermore, availability of glucose has been hypothesized to maintain 
sufficient calcium buffering and memory formation in hippocampus, with 
implications in Alzheimer’s disease (Holahan, 2019). Together, these 
independent results from other fields associate our results on FGF21 
dependent glucose uptake and mitochondrial regulation in CA2 in a frame 
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where FGF21 serves important functions in maintaining adaptive responses in 
central nervous system, especially upon mitochondrial pathology. 
In the literature, CA2 has emerged with connections to hypothalamus. The 
most prominent extra-hippocampal connectivity of CA2 are directly with 
paraventricular nucleus of hypothalamus (PVN) and supramammillary 
nucleus of hypothalamus (SUM) (Cui, 2013; Kohara, 2014). Interestingly, 
SUM can be found to express FGF21 as the ninth most upregulated gene 
relative to other brain areas [Harmonizome-database (Rouillard, 2016)]. 
Furthermore, systemically administered FGF21 has been directly shown to 
activate neurons of the PVN (Santoso, 2017; Matsui, 2018). 
Metabolic hormones from the periphery are known to modify synaptic 
messaging and hypothalamic regulation of metabolism indirectly through 
other brain areas, such as hippocampus and cortex (comment in Maffei and 
Mainardi 2019). Interestingly, such mechanisms have indeed been reported 
for GDF15, another hormonal factor induced as part of the ISRmt. GDF15 was 
shown to bind to extra-hypothalamic receptors, through which the hormone 
mediates regulation of metabolism, important in adaptation to non-
homeostatic stressful conditions (Hsu, 2017). With playful thinking, these 
findings spark interesting speculation whether the hypothalamic regions with 
FGF21 expression or receptors for peripheral FGF21 could mediate for 
example behavioral or other yet uncharacterized adaptive responses via the 
hippocampal CA2. 
5.5 FGF21 MARKS THE TISSUE-SPECIFIC 
MANIFESTATION OF RESPIRATORY CHAIN 
DEFICIENCY CAUSED BY MTDNA DELETIONS (I 
AND III*) 
In summary, previous results and data presented in this thesis show that the 
ubiquitously expressed dominant Twinkle mutant protein causes mtDNA 
mutagenesis specifically in the skeletal muscle, heart and brain of Deletor 
mouse (and AdPEO patients). In this thesis, we demonstrate that the mtDNA 
deletion pathology in the brain and muscle differ in many aspects, especially 
in relation to FGF21-signaling. Overall, these key differences unravel new 
tissue-specific features for Twinkle and mtDNA deletion pathophysiology, and 
highlight the importance of secondary messengers even as potential drivers of 
the mitochondrial deficiency. See the following bullet-points for the summary: 
 
• FGF21 and other transcriptional components of AARE/ISRmt are induced 
in muscle tissues but not in the brain of Deletor. Moreover, the metabolic 
fingerprints are not similar in the muscle and (dorsal) hippocampus of 
Deletors. Especially in hippocampus, however, the heterogeneity of the cell 
populations challenges the bulk analysis of metabolome.   
 63 
•! mTORC1 activation is a distinctive hallmark of pathogenesis in the muscle 
but not in the brain (Figure 17). 
•! FGF21 does not affect the marks of respiratory chain deficiency of the 
muscle but completely shapes the mitochondrial and metabolic response 
in CA2 (Figure 17). 
 
Figure 17' Comparison of respiratory chain activity (top), mTORC1 activation (bottom) in 
muscle and brain. The effect of FGF21 for those readouts concluded for the  CA2 of 
hippocampus and skeletal muscle.  
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5.5.1 FGF21, FOR BETTER OR WORSE?  
Deletor is a physiological model of mitochondrial myopathy with a relatively 
mild progressive phenotype and normal lifespan. So far, the only robust 
behavioral phenotype is increased motor activity in treadmill (Tyynismaa, 
2005). Other functional markers for scoring the phenotype are not available, 
and the assessment of pathology is based on histological and molecular signs, 
primarily mtDNA deletions and respiratory chain deficiency. For example, in 
a recent treatment study performed with Deletor, inhibition of mTORC1 by 
rapamycin brought down the ISRmt, including FGF21, and fundamentally 
decreased COX-/SDH+ fibers and mtDNA deletion load in skeletal muscle, 
interpreted as improvement of the phenotype (Khan, 2017). For FGF21 alone, 
we report more subtle fine-tuning of the advanced stage metabolic 
rearrangements of the mitochondrial myopathy muscle (5.3). In the CA2 of 
Deletors, on the other hand, Complex IV amount was - surprisingly - 
completely dependent on FGF21 presence, suggesting FGF21-mediated 
pathology (5.4). These finding call for further studies on pathological 
mechanisms, suggesting contribution of both mtDNA deletions and 
metabolism in the manifestation of OXPHOS deficiency.  
FGF21 has reported associations in regulation of mitochondrial biogenesis 
and fitness that are suggested to be mediated through activation of 
PGC1a(peroxisome proliferator-activated receptor c co-activator 1a) for 
example in cultured dopaminergic neurons (Mäkelä, 2014) and in the liver 
(Potthoff, 2009). In simplified terms, PGC1a	is a master regulator of responses 
that induce activity of mitochondria (Fernandez-Marcos, 2011), where 
protection of cellular fitness in various stresses involve mitochondrial 
biogenesis, boosting of respiratory capacity and ROS metabolism (Austin, 
2012). In Deletor, treatment trials with ketogenic diet and B3-vitamin 
supplementation both increased mitochondrial biogenesis and improved the 
muscle pathology (Ahola-Erkkila, 2010; Khan, 2014). Additionally, a direct 
PGC1a activation strategy with bezafibrate treatment improved the muscle 
pathology in isolated Complex IV deficiency mouse model, Surf1KO (Viscomi, 
2011), and in the Deletor (Yatsuga, 2012), but bezafibrate also caused adverse 
effects on the liver in Deletor.	 Furthermore, although mitochondrial 
proliferation and mtDNA copy number variation are not directly analogous 
events, increasing the mtDNA quantity, even with a pathologically high 
proportion of mutated mtDNA (>75%), was shown to alleviate the molecular 
pathogenesis of a mitochondrial translation and OXPHOS deficiency mouse 
model (Filograna, 2019).  
On the contrary, evidence of FGF21-mediated deleterious effects in context 
of detrimental mitochondrial dysfunction has been reported. Conditional 
OPA1 knockout in muscle (OPA1KOmuscle mouse) results in severe muscle 
atrophy, rapid body weight loss and death by 100 days of life (Tezze, 2017). 
Comprehensive knockout of OPA1 is lethal in embryogenesis (Davies, 2007), 
emphasizing the essential nature of the protein. In OPA1KOmuscle mouse, the 
FGF21 response was described to be deleterious through promotion of 
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systemic inflammation, since knockout of FGF21 in the OPA1KOmuscle 
background ameliorated the phenotype and prolonged lifespan (Tezze, 2017). 
As mentioned, in Deletor mouse the lifespan is normal and functional effects 
of the pathological mutation are mild but we have not detected worsening of 
locomotion or physical condition in the DEL-FKO mice, and we have not 
detected signs inflammation. The different outcomes could be explained by the 
outstanding difference in severity of the mitochondrial insult in the OPA1KO 
and the Deletor mice. For example, the earlier fatality of FGF21 expressing 
OPA1KO could simply lie also in complete shutdown of mitochondria and 
severe muscle loss in combination with significant weight loss and altered 
energy metabolism due to systemic actions of FGF21.  
5.6 FGF21 AND GDF15 ARE CLINICALLY RELEVANT 
PROTEIN BIOMARKERS FOR MITOCHONDRIAL 
MYOPATHIES (II) 
Our research group was first to characterize FGF21 as a circulating diagnostic 
biomarker for mitochondrial diseases (Suomalainen, 2011), and others have 
replicated the finding in mitochondrial myopathies (Davis, 2013; Koene, 2014; 
Fujita, 2015; Yatsuga, 2015). Later on, also GDF15 emerged as mitochondrial 
disease biomarker (Fujita, 2015; Yatsuga, 2015). We aimed to review the 
specificity and sensitivity of the two protein biomarkers simultaneously in 
mitochondrial and non-mitochondrial diseases and conditions.  
In clinically relevant retrospective analysis of patient samples, we found 
that among muscle manifesting diseases, both FGF21 and GDF15 were able to 
identify mitochondrial disorders from non-mitochondrial myopathies, with 
specificity and sensitivity exceeding the performance of conventional serum 
biomarkers such as lactate, pyruvate, or creatine kinase (Suomalainen, 2011). 
However, serum GDF15 showed generally high values among multiple 
secondary non-mitochondrial conditions, including cardiomyopathy, biliary 
cirrhosis, primary sclerosing cholangitis, metastasizing colorectal cancer and 
nonagenarians. This was not surprising, as GDF15 is known to be induced in a 
spectrum of conditions and considered as metabolic biomarker of generalized 
mortality (Corre, 2013). FGF21 levels also showed single high values for the 
metastasizing colorectal cancer cases, likely indicative of secondary liver 
pathology (Dushay, 2010; Yilmaz, 2010).  
Overall, our results were in line with the original publications, and 
considered both markers useful in clinical diagnostics upon suspected 
mitochondrial disease, but also highlighted considerations regarding 
comorbidities amongst the heterogeneous population of adult patients.  
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5.7 INDUCTION OF FGF21 AND GDF15 SUGGEST 
CLINICALLY RELEVANT MITOCHONDRIAL 
TRANSLATION DEFECT (II) 
We noticed that a minority of mitochondrial disease patients in our cohort 
showed low FGF21 and GDF15 values, despite having a confirmed 
mitochondrial disease diagnosis. This raised the hypothesis that specific types 
of mitochondrial dysfunction might elicit different responses. Those patients 
with low levels of biomarkers manifested diseases with underlying mutation 
directly affecting the structure of the respiratory chain, whereas majority of 
the patients with high FGF21 values had mutations affecting the maintenance 
and expression of mtDNA. Therefore, we wanted to more systematically 
review the mechanism of induction for FGF21 and GDF15 in mitochondrial 
diseases and conducted a composite study of meta-analysis (based on: Davis, 
2013; Suomalainen, 2011; Yatsuga, 2015) and retrospective measurements in 
mitochondrial patients. Additionally, six mouse models with different types of 
representative mitochondrial defects were studied to confirm the findings.  
5.7.1 CLINICAL CHARACTERISTICS OF THE STUDY SUBJECTS  
According to the best of our knowledge, primary manifestations in the central 
nervous system caused by mitochondrial dysfunction, without muscle 
involvement, do not induce an FGF21 response detectable in the serum of 
patients. In mice, however, a severe disruption of mitochondrial fission 
through Drp1 ablation in neurons was reported to induce FGF21 in the central 
nervous system (Restelli, 2018). For clarity, all patients included to the study 
had a genetic diagnosis and muscle-manifesting (biochemical, molecular or 
histological) mitochondrial defect.  
We then further divided the mitochondrial myopathy patients into three 
groups, according to their underlying genetic causes: 1) isolated RC subunit or 
assembly factor defects, 2) mtDNA maintenance defects and 3) mitochondrial 
protein synthesis defects (Figure 18). The most prevalent diseases of these 
three groups were Leigh disease, PEO/mitochondrial myopathy and MELAS, 
respectively. For more detailed description of the diseases, see chapter 2.4. 
The mouse models were chosen to represent similar mechanisms and 
follow the same criteria for muscle manifestation (Figure 18). For primary 
OXPHOS deficiency, we studied samples from two well characterized models: 
knockout of nuclear encoded Ndufs4 (Kruse, 2008) and Surf1 (Dell’Agnello, 
2007) that compromise Complex I activity and Complex IV assembly, 
respectively. The NDUFS4KO mouse mimics the phenotype of Leigh patients 
with bilateral brain lesions and premature death. In humans, SURF1 
mutations also cause Leigh (2.4.2), but the knockout mice show no 
neurodegeneration and live longer than wild type mice, although the Complex 
IV deficiency is evident in the muscle tissue. For mtDNA maintenance 
diseases, we analyzed mice with Twinkle mutations: the Deletor (Tyynismaa, 
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2005) and a mouse expressing a Twinkle point mutation (K320E) only in the 
skeletal muscle (Baris, 2015), both manifesting with multiple mtDNA 
deletions and mosaic respiratory chain deficiency in the skeletal muscle. We 
also included Mitomice, harboring a single, heteroplasmic mtDNA deletion 
(Inoue, 2000). MPV17 is a mitochondrial inner membrane protein with 
disease causing mutations underlying hepatocerebral mtDNA depletion 
disease (Spinazzola, 2006). The MPV17 knockout mouse manifests a kidney 
disease and significant depletion of mtDNA in the muscle, with 5-6 percentage 
of COX-negative muscle fibers (Spinazzola, 2006; Viscomi, 2009). At the time 
of our biomarker study, no mouse model of primary mtDNA point mutations 
were available, e.g. mimicking the common tRNA-related diseases like MELAS 
or MERRF. Rather recently, a mouse with a heteroplasmic mtDNA mutation 
in tRNAAla (not a patient mutation) was described,  manifesting in the muscle 
with a mild defect in mitochondrial translation and respiratory chain 
(Kauppila, 2016), but measurements of Fgf21 or other stress response genes 
have not been reported. 
 
Figure 18' Outline of the diseases and genetic causes that represent the three categories of 
mitochondrial myopathy in publication II. Visuals: red arrows on the right-hand 
side illustrate secondary causative relationship of the defects, blue text indicates 
primary mutation in the mtDNA. 
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The samples from patients and mouse models analyzed in this study shared a 
similar pattern for serum FGF21 and GDF15. We discovered that both 
biomarkers were high in circulation of subjects with mitochondrial protein 
synthesis and mtDNA maintenance diseases. Patients and mice with 
mutations (or knockout) that directly affect the respiratory chain had 
biomarker levels comparative to healthy controls (Figure 19).  
From the mouse models, we also analyzed Fgf21 expression in the affected 
skeletal muscle. In mice with mtDNA deletions (Deletor, TwinkleK320E and 
Mitomice), expression of Fgf21 was induced in skeletal muscle, whereas the 
single respiratory chain complex mutants (SURF1KO and NDUFS4KO) and 
mtDNA depletion model (MPV17KO) showed normal expression (Figure 19). 
In the muscles of Mitomice, the determined mtDNA deletion load (percentage 
of molecules with deletions) positively correlated with Fgf21 expression and 
serum FGF21.  
In summary, our results indicated that among mitochondrial myopathies, 
a primary or secondary mitochondrial protein synthesis defect is needed for 
induction of FGF21 and GDF15.  
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Figure 19 Top panel: Serum FGF21 and GDF15 levels in mitochondrial disease patients, 
median and interquartile range presented with whiskers. Bottom panel: Serum 
FGF21 and skeletal muscle Fgf21 expression in mouse models, average and 
standard error of mean presented with bar and whiskers. Statistical significance: 
*=p<0.05, **=p<0.01, ***=p<0.001. ****=p<0.0001. 
As mentioned earlier, physiological mouse models for MELAS and other 
primary mtDNA protein synthesis diseases still do not exist, and therefore 
parallel assessment of stress responses and mechanism of molecular and 
biochemical pathology was not feasible. A large proportion of mitochondrial 
translation diseases are, however, caused by mutations in nuclear encoded 
mitochondrial aminoacyl tRNA synthetases (mt-aaRSs). Encephalopathy is 
the most common manifestation of human mt-aaRS syndromes, but heart and 
skeletal muscle specific knockout of Dars2 (mitochondrial aspartyl-tRNA 
synthetase) is a technical model for severe mitochondrial translation 
deficiency of non-neuronal tissue (Dogan, 2014). Importantly, in the heart of 
Dars2KO mouse, robust induction of expression and secretion of FGF21 
precedes the histological hallmarks of mitochondrial dysfunction. These 
results agree with ours and support the conclusion that mtDNA translation or 
expression deficiency induces the stress response involving FGF21 induction.  
Mitochondrial translation diseases are categorically respiratory chain 
disorders, but the complexity and comprehensiveness of the cellular responses 
goes far beyond functions needed for mitochondrial protein synthesis and 
OXPHOS inside mitochondria (Suomalainen, 2018). In clinical context, our 
results and conclusions of primary or secondary mtDNA expression defect as 
inducer of FGF21 and GDF15 are valuable but the molecular and biochemical 
mechanisms remain to be studied further. In the lack of robust mouse models 
for mitochondrial translation diseases, in vitro settings have served the 
purpose. As an example, effects of two different chemical inhibitors of 
mitochondrial translation are discussed here below.  
Mitochondrial translation shares many ancestral features with prokaryotic 
systems, leaving the mitoribosomes vulnerable to some commonly used 
antibiotics, relevant in clinics where routine treatment might cause 
unexpected adverse effects (Singh, 2014). Actinonin is a small molecule 
inhibitor of mitochondrial protein synthesis. Depletion of mitochondrial 
translation products by actinonin is followed by significant detrimental 
consequences for cellular fitness, as evidenced by a loss of membrane potential 
and reversible fragmentation of mitochondrial network (Richter, 2013, 2015). 
Richter et al. demonstrate that the compromised mitochondrial fitness and 
protein synthesis by actinonin are caused by impaired turnover or translation 
products, leading to accumulation of mistranslated mitochondrial 
polypeptides in the inner mitochondrial membrane (Richter, 2015, 2019). 
Interestingly, the detrimental effects of actinonin on mitochondrial fitness can 
be prevented by blocking protein synthesis by another drug, chloramphenicol. 
Chloramphenicol blocks the A-site on the mitochondrial ribosome, preventing 
mitochondrial protein synthesis, and therefore, double exposure prevents 
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elongation and essentially insertion of mistranslated products into the 
membrane. Importantly, the mitochondrial network and cellular proliferation 
are preserved in chloramphenicol, and FGF21 together with other ISRmt genes 
do not get induced, whereas actinonin ignites a strong stress response from 
the nucleus (Richter, 2013; chapter 5.2.1). This mechanism could be seen 
mechanistically relevant for mitochondrial disease models and patients. For 
example, in a cell-culture model system for MERRF mutation (homoplasmic 
8344A>G in MT-TK), stalling of translation machinery on lysine codons due 
to lack of mitochondrial tRNALys, leads to accumulation of an aberrant 
mitochondrial translation product (MT-CO1) (Enriquez, 1995; Richter, 2015), 
and in MERRF patients high amount of FGF21 is seen in serum (Su, 2012).  
After discussing these concepts, the mechanistic trigger for ignition of 
FGF21 signaling in mitochondrial protein synthesis defects (primary or 
secondary) could be hypothesized to involve mitochondrial membrane stress 
or remodeling. However, the multiple steps between the primary 
mitochondrial stress and the induction of nuclear stress responses (involving 
systemic signaling) remain unknown, and require more mechanistic research 
in the future. 
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6 CONCLUSIONS  
Mitochondrial diseases are metabolic disorders presenting with extreme 
variability of tissue-specific consequences. The reasons for those 
manifestations cannot be explained merely by genetic causes or impaired 
function of OXPHOS and consequent lack of ATP. Studies of this thesis have 
utilized valuable patient material and disease models to shed light into 
pathophysiology of mitochondrial diseases by characterizing the stress 
responses in the primarily and secondarily affected tissues. Moreover, to study 
the effects of FGF21 in mitochondrial disease context, a new Deletor-FGF21KO 
mouse model was generated and characterized in this thesis.  
In the first part of this thesis, we described a novel, well-conserved  
metabolic fingerprint for mitochondrial myopathy caused by mtDNA 
maintenance defects. In summary, the affected muscle tissues of AdPEO 
patients and Deletor mouse presented with remodeling of one-carbon, folate 
and nucleotide metabolism, as well as induction of glutathione synthesis in 
transsulfuration. Importantly, in vivo glucose uptake and flux analyses 
showed that the induction of one-carbon metabolism and transsulfuration 
were dependent on glucose-driven serine de novo synthesis in Deletor muscle 
and heart. These mechanisms that typically mark the survival of proliferative 
cancer were a completely novel feature for the post-mitotic muscle with 
mtDNA instability and mitochondrial dysfunction.  
Second, we showed that the ISRmt, comprising of the transcriptional and 
metabolic programs, progresses sequentially in interdependent stages, and 
likely involves regulation by several ATFs. The first-stage ISRmt co-appeared 
with the first respiratory chain deficient fibers, and included expression of 
FGF21 and GDF15, mitochondrial folate cycle enzyme MTHFD2 and 
regulatory transcription factor ATF5. According to expression of PHGDH and 
PSAT1 enzymes, the induction of glucose-driven serine synthesis and 
transsulfuration initiated months after the first stage, only after advanced 
mitochondrial pathology was detected in the muscle (ragged-red fibers). 
Importantly, we showed that in the absence of FGF21 (Deletor-FGF21KO 
mice), no induction of serine biosynthesis, transsulfuration or methyl cycle 
rearrangements occurred. However, the molecular and histological hallmarks 
of muscle pathology or the first-stage ISRmt were not modified by presence or 
absence of FGF21. This suggested that induction of the first-line ISRmt 
markers, namely FGF21, is important for the metabolic regulation in the 
mitochondrial myopathy muscle. 
The normal physiological role for FGF21 is to serve transient metabolic 
rewiring to sustain low-nutrient conditions, for example. When chronically 
expressed from the affected muscles upon mitochondrial disease, the 
physiological consequences for this hormone remain unclear. Understanding 
the local and systemic regulation of energy metabolism by such ‘myokines’ is 
Conclusions 
72 
of high importance e.g. when dietary interventions are considered in patients. 
Our results on Deletor-FGF21KO model suggested that the chronic FGF21-
response had different outcomes depending on the target tissue. Systemically, 
FGF21 caused loss of adiposity and browning of the white adipose. Moreover, 
the tissue-level glucose preferences were widely altered in the brain and 
periphery of the Deletor. Additionally, we encountered a completely novel 
manifestation for mtDNA maintenance defect in the central nervous system 
that showed undisputed dependence on FGF21. First, we showed that the 
ubiquitous expression of mutated Twinkle causes uniform mtDNA deletion 
formation the brain of Deletor, regardless of FGF21 status. Yet, specifically 
only the CA2-region of hippocampus manifested mitochondrial pathology 
coupled to intensive glucose uptake, both of which were completely FGF21-
dependent. Essentially, the regulation of pathological manifestation by FGF21 
was different in the muscle and the brain. Therefore, our results reveal tissue-
specific regulation of mitochondrial metabolism designated by FGF21. Further 
studies utilizing the Deletor and Deeltor-FGF21KO models are needed to 
understand the non-homeostatic, tissue-specific pathophysiology and 
regulation of energy metabolism by FGF21. 
Transcriptomic analysis of human and mouse samples (as well as cell-
culture experiments) showed that in mtDNA deletion disorders and 
mitochondrial translation defects, importance of the classical UPRmt-response 
was minor compared to the ISRmt. This suggests that the well-established 
UPRmt of invertebrates was not robustly induced in the mammalian muscle by 
mtDNA deletions but could still serve important functions upon different 
insults, for example in childhood-onset neurodegenerative mitochondrial 
disorders caused by direct disruption of OXPHOS subunits. This concept of 
different or alternative stress responses among mitochondrial (OXPHOS) 
diseases caused by different molecular mechanisms was highlighted in the 
biomarker study of this thesis (publication II). In our combined meta-analysis 
and retrospective measurement of serum FGF21 and GDF15 in patients and 
representative mouse models, we reported that the biomarkers were robustly 
induced upon primary or secondary defects of mtDNA translation but were 
not induced by isolated OXPHOS deficiency. These results on UPRmt and 
ISRmt highlight the need to specify the disease mechanisms and stress 
responses when studying the pathophysiology of mitochondrial diseases.  
Together, results presented in this thesis offer comprehensive description 
of the pathophysiological events in mitochondrial myopathy. We describe 
conservation of the transcriptional and metabolic stress responses in 
mammalian systems with mtDNA maintenance or expression defects. 
Furthermore, we demonstrate sequential progression for the mammalian 
ISRmt with tissue-specific regulation of the metabolic pathology by FGF21. Our 
data on context-dependent stress responses unlock new directions for future 
research, and offer tools for diagnostics as well as follow-up and management 
of mitochondrial disease progression. 
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